WO2024074571A1 - Dc-targeting vaccine against nipah virus infection - Google Patents
Dc-targeting vaccine against nipah virus infection Download PDFInfo
- Publication number
- WO2024074571A1 WO2024074571A1 PCT/EP2023/077477 EP2023077477W WO2024074571A1 WO 2024074571 A1 WO2024074571 A1 WO 2024074571A1 EP 2023077477 W EP2023077477 W EP 2023077477W WO 2024074571 A1 WO2024074571 A1 WO 2024074571A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- seq
- antibody
- acid sequence
- niv
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 72
- 208000000464 Henipavirus Infections Diseases 0.000 title description 7
- 206010064034 Nipah virus infection Diseases 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 112
- 241000526636 Nipah henipavirus Species 0.000 claims abstract description 91
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 82
- 229920001184 polypeptide Polymers 0.000 claims abstract description 70
- 239000000427 antigen Substances 0.000 claims abstract description 36
- 108091007433 antigens Proteins 0.000 claims abstract description 36
- 102000036639 antigens Human genes 0.000 claims abstract description 36
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 80
- 210000004027 cell Anatomy 0.000 claims description 55
- 101150013553 CD40 gene Proteins 0.000 claims description 52
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 49
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 25
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 18
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 102100035359 Cerebellar degeneration-related protein 2-like Human genes 0.000 claims description 15
- 101000737792 Homo sapiens Cerebellar degeneration-related protein 2-like Proteins 0.000 claims description 15
- 101001057154 Homo sapiens Melanoma-associated antigen D2 Proteins 0.000 claims description 8
- 102100027251 Melanoma-associated antigen D2 Human genes 0.000 claims description 8
- 101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 claims description 5
- 101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 claims description 5
- -1 mAb4 Proteins 0.000 claims description 5
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 108090000623 proteins and genes Proteins 0.000 abstract description 52
- 102000004169 proteins and genes Human genes 0.000 abstract description 29
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 25
- 241000699670 Mus sp. Species 0.000 abstract description 21
- 238000006386 neutralization reaction Methods 0.000 abstract description 17
- 230000004044 response Effects 0.000 abstract description 17
- 101710141454 Nucleoprotein Proteins 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000005867 T cell response Effects 0.000 abstract description 6
- 230000000890 antigenic effect Effects 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 5
- 229940125575 vaccine candidate Drugs 0.000 abstract description 5
- 230000036755 cellular response Effects 0.000 abstract description 4
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 231100000673 dose–response relationship Toxicity 0.000 abstract description 2
- 231100000636 lethal dose Toxicity 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract description 2
- 101150106931 IFNG gene Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 109
- 241001465754 Metazoa Species 0.000 description 43
- 241000282552 Chlorocebus aethiops Species 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 19
- 230000028993 immune response Effects 0.000 description 19
- 108091006027 G proteins Proteins 0.000 description 15
- 108091000058 GTP-Binding Proteins 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 102000030782 GTP binding Human genes 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 241000700605 Viruses Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 208000020007 Autosomal agammaglobulinemia Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
- 108010029697 CD40 Ligand Proteins 0.000 description 7
- 229940123189 CD40 agonist Drugs 0.000 description 7
- 102100032937 CD40 ligand Human genes 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000562 conjugate Substances 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000008348 humoral response Effects 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 230000002516 postimmunization Effects 0.000 description 7
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 239000012648 POLY-ICLC Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 229940115270 poly iclc Drugs 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 108700002563 poly ICLC Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 description 4
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 description 4
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 4
- 101000926057 Human herpesvirus 2 (strain G) Envelope glycoprotein C Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000001280 germinal center Anatomy 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000893570 Hendra henipavirus Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101100075831 Caenorhabditis elegans mab-7 gene Proteins 0.000 description 2
- 101100313161 Caenorhabditis elegans mab-9 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 208000032163 Emerging Communicable disease Diseases 0.000 description 2
- 102100023721 Ephrin-B2 Human genes 0.000 description 2
- 108010044090 Ephrin-B2 Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000766965 Homo sapiens C-type lectin domain family 4 member K Proteins 0.000 description 2
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 2
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 description 2
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 2
- 238000012450 HuMAb Mouse Methods 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 2
- 102100029607 Interferon-induced protein 44 Human genes 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 101000830098 Nipah virus Glycoprotein G Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 210000001102 germinal center b cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000016788 immune system process Effects 0.000 description 2
- 230000000899 immune system response Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000012448 transchromosomic mouse model Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 1
- 102100028672 C-type lectin domain family 4 member D Human genes 0.000 description 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100023733 Ephrin-B3 Human genes 0.000 description 1
- 108010044085 Ephrin-B3 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000035314 Henipavirus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 1
- 101000766905 Homo sapiens C-type lectin domain family 4 member D Proteins 0.000 description 1
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101001018258 Homo sapiens Macrophage receptor MARCO Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000595918 Homo sapiens Phospholipase A and acyltransferase 4 Proteins 0.000 description 1
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102100033272 Macrophage receptor MARCO Human genes 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 101000602426 Nipah virus Nucleoprotein Proteins 0.000 description 1
- 208000016045 Nipah virus disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 1
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 241000288675 Pteropodidae Species 0.000 description 1
- 241000289052 Pteropus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 1
- 102100032855 Sialoadhesin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000009809 T cell chemotaxis Effects 0.000 description 1
- 229940124614 TLR 8 agonist Drugs 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 108010045512 cohesins Proteins 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000045167 human CD207 Human genes 0.000 description 1
- 230000024934 humoral immune response mediated by circulating immunoglobulin Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000014038 regulation of leukocyte activation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18271—Demonstrated in vivo effect
Definitions
- Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus first recognized following a 1998-99 outbreak of severe febrile encephalitis in Malaysia and Singapore (Chua, K. B., et al. "Nipah virus: a recently emergent deadly paramyxovirus.” Science 288.5470 (2000): 1432-1435.).
- the Bangladesh strain (NiVB) has caused repeated outbreaks, varying in number, in Bangladesh and northeast India with outbreaks occurring almost every year between 2001–2015.
- the outbreaks of NiVB have had high case fatality rate averaging about 75% (Lo, Michael K., et al. "Characterization of Nipah virus from outbreaks in Bangladesh, 2008–2010.” Emerging infectious diseases 18.2 (2012): 248.) with human-to- human transmission often observed (Gurley, Emily S., et al. "Person-to-person transmission of Nipah virus in a Bangladeshi community.” Emerging infectious diseases 13.7 (2007): 1031.). Multiple candidate vaccines exist, but all are in the preclinical stages.
- rVSV vectors expressing Nipah virus G are prime candidates for new ‘emergency vaccines’ to be utilized for outbreak management (Foster, Stephanie L., et al. "A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.” Proceedings of the National Academy of Sciences 119.12 (2022): e2200065119.), concerns remain about safety, development and inadequate transport/storage in affected areas. Thus, improving the ability of vaccines to induce strong, cellular and humoral immune responses, placing them as a new generic vaccine platform for prophylactic strategies but also at the heart of a therapeutic arsenal remains the challenge to rapidly and efficiently respond to Nipah.
- the present invention is defined by the claims.
- the present invention relates to antibodies that are directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to the Nipah virus antigenic polypeptides.
- DETAILED DESCRIPTION OF THE INVENTION Definitions: As used herein, the term "subject” or “subject in need thereof", is intended for a human or non-human mammal. Typically the patient is affected or likely to be infected with Nipah virus.
- Nipah virus has its general meaning in the art and refers to a virus that is a member of the Paramyxoviridae family and is related to the Hendra virus (formerly called equine morbillivirus).
- the Nipah virus was initially isolated in 1999 upon examining samples from an outbreak of encephalitis and respiratory illness among adult men in Malaysia and Singapore (see, e.g., Chua et al., Lancet. October 9, 1999;354(9186):1257-9 and Paton et al., Lancet. October 9, 1999;354(9186):1253-6).
- Nipah virus comprises a 6-gene, 18.2-kb, negative-sense single-stranded RNA (ssRNA) genome, which encodes 9 proteins: nucleoprotein (N), phosphoprotein (P), the interferon antagonists W and V, the viral C protein, a matrix protein (M), viral fusion and glycoproteins (F and G, respectively), and a large polymerase (L).
- ssRNA negative-sense single-stranded RNA
- N nucleoprotein
- P phosphoprotein
- W and V the interferon antagonists
- M matrix protein
- F and G fusion and glycoproteins
- L large polymerase
- G protein refers to the Nipah virus glycoprotein G.
- the G protein has a globular head domain formed of a six-bladed beta sheet-propeller, connected via a flexible stalk domain to a transmembrane anchor.
- the G protein binds to the cellular receptors ephrin B2 and ephrin B3, mediating viral attachment. Following attachment Nipah Virus glycoprotein G undergoes a conformational change that leads to triggering of glycoprotein F which leads to membrane fusion.
- An exemplary amino acid sequence for the G protein is represented by SEQ ID NO:1.
- Nipah virus glycoprotein F is a class I fusion protein, with typical structural features. These include heptad repeats and a hydrophobic fusion peptide that bind to each other, forming a six-helix bundle which functions in membrane fusion processes. Nipah Virus attaches to target cells via glycoprotein G, which then undergoes a conformational change leading to triggering of Nipah virus glycoprotein F which leads to membrane fusion.
- An exemplary amino acid sequence for the F protein is represented by SEQ ID NO:2.
- N The encapsidated genomic RNA is termed the nucleocapsid (NC) and serves as template for transcription and replication.
- An exemplary amino acid sequence for the N protein is represented by SEQ ID NO:3.
- SEQ ID NO:3 >sp
- a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, and may be interrupted by non-nucleotide components. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer.
- the term polynucleotide, as used herein, refers interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form.
- the expression “derived from” refers to a process whereby a first component (e.g., a first polypeptide), or information from that first component, is used to isolate, derive or make a different second component (e.g., a second polypeptide that is different from the first one).
- a first component e.g., a first polypeptide
- a second component e.g., a second polypeptide that is different from the first one
- the term "encoding" refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as, for example, a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (e.g., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
- a gene, cDNA, or RNA encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
- nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence.
- nucleotide sequence that encodes a protein or a RNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).
- the terms “vector”, “cloning vector” and “expression vector” mean the vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence.
- promote expression e.g., transcription and translation
- promoter/regulatory sequence refers to a polynucleotide sequence (such as, for example, a DNA sequence) recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence, thereby allowing the expression of a gene product operably linked to the promoter/regulatory sequence.
- this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product.
- the promoter/regulatory sequence may, for example, be one which expresses the gene product in a tissue specific manner.
- the term "operably linked” or “transcriptional control” refers to functional linkage between a regulatory sequence and a heterologous polynucleotide sequence resulting in expression of the latter. For example, a first polynucleotide sequence is operably linked with a second polynucleotide sequence when the first polynucleotide sequence is placed in a functional relationship with the second polynucleotide sequence.
- a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
- Operably linked DNA sequences can be contiguous with each other and, e.g., where necessary to join two protein coding regions, are in the same reading frame.
- transformation means the introduction of a "foreign” (i.e., extrinsic or extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell will express the introduced gene or sequence to produce a desired substance, typically a protein or enzyme coded by the introduced gene or sequence.
- a host cell that receives and expresses introduced DNA or RNA bas been "transformed".
- the term "expression system” means a host cell and compatible vector under suitable conditions, e.g., for the expression of a protein coded for by foreign DNA carried by the vector and introduced to the host cell.
- the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described below.
- the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch algorithm (Needleman, Saul B. & Wunsch, Christian D. (1970). "A general method applicable to the search for similarities in the amino acid sequence of two proteins". Journal of Molecular Biology.48 (3): 443–53.).
- the percent identity between two nucleotide or amino acid sequences may also be determined using for example algorithms such as EMBOSS Needle (pair wise alignment; available at www.ebi.ac.uk).
- EMBOSS Needle may be used with a BLOSUM62 matrix, a “gap open penalty” of 10, a “gap extend penalty” of 0.5, a false “end gap penalty”, an “end gap open penalty” of 10 and an “end gap extend penalty” of 0.5.
- the “percent identity” is a function of the number of matching positions divided by the number of positions compared and multiplied by 100. For instance, if 6 out of 10 sequence positions are identical between the two compared sequences after alignment, then the identity is 60%. The % identity is typically determined over the whole length of the query sequence on which the analysis is performed. Two molecules having the same primary amino acid sequence or polynucleotide sequence are identical irrespective of any chemical and/or biological modification.
- a first amino acid sequence having at least 80% of identity with a second amino acid sequence means that the first sequence has 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99 or 100% of identity with the second amino acid sequence.
- conjugate or interchangeably “conjugated polypeptide” is intended to indicate a composite or chimeric molecule formed by the covalent attachment of one or more polypeptides.
- conjugation means that the polypeptide and the non-peptide moiety are either directly covalently joined to one another, or else are indirectly covalently joined to one another through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties.
- a particular conjugate is a fusion protein.
- fusion protein indicates a protein created through the attaching of two or more polypeptides which originated from separate proteins. In particular fusion proteins can be created by recombinant DNA technology and are typically used in biological research or therapeutics. Fusion proteins can also be created through chemical covalent conjugation with or without a linker between the polypeptides portion of the fusion proteins.
- the two or more polypeptide are fused directly or via a linker.
- the term "directly” means that the first amino acid at the N-terminal end of a first polypeptide is fused to the last amino acid at the C-terminal end of a second polypeptide.
- This direct fusion can occur naturally as described in (Vigneron et al., Science 2004, PMID 15001714), (Warren et al., Science 2006, PMID 16960008), (Berkers et al., J. Immunol.2015a, PMID 26401000), (Berkers et al., J.
- linker has its general meaning in the art and refers to an amino acid sequence of a length sufficient to ensure that the proteins form proper secondary and tertiary structures.
- the linker is a peptidic linker which comprises at least one, but less than 30 amino acids e.g., a peptidic linker of 2-30 amino acids, preferably of 10-30 amino acids, more preferably of 15-30 amino acids, still more preferably of 19-27 amino acids, most preferably of 20-26 amino acids.
- the linker has 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30 amino acid residues.
- linkers are those which allow the compound to adopt a proper conformation.
- linker sequences (1) will adopt a flexible extended conformation, (2) will not exhibit a propensity for developing ordered secondary structure which could interact with the functional domains of fusion proteins, and (3) will have minimal hydrophobic or charged character which could promote interaction with the functional protein domains.
- antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds to an antigen.
- two heavy chains are linked to each other by disulfide bonds, and each heavy chain is linked to a light chain by a disulfide bond. There are two types of light chains, lambda (1) and kappa (k).
- the heavy chain classes which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each chain contains distinct sequence domains.
- the light chain includes two domains, a variable domain (VL) and a constant domain (CL).
- the heavy chain includes four domains, a variable domain (VH) and three constant domains (CH1, CH2 and CH3, collectively referred to as CH).
- the variable regions of both light (VL) and heavy (VH) chains determine binding recognition and specificity to the antigen.
- the constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans- placental mobility, complement binding, and binding to Fc receptors (FcR).
- the Fv fragment is the N-terminal part of the Fab fragment of an immunoglobulin and consists of the variable portions of one light chain and one heavy chain.
- the specificity of the antibody resides in the structural complementarity between the antibody combining site and the antigenic determinant.
- Antibody combining sites are made up of residues that are primarily from the hypervariable or complementarity determining regions (CDRs). Occasionally, residues from non-hypervariable or framework regions (FR) can participate in the antibody binding site, or influence the overall domain structure and hence the combining site.
- Complementarity Determining Regions or CDRs refer to amino acid sequences that together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site.
- the light and heavy chains of an immunoglobulin each have three CDRs, designated L-CDR1, L-CDR2, L- CDR3 and H- CDR1, H-CDR2, H-CDR3, respectively.
- An antigen-binding site therefore, typically includes six CDRs, comprising the CDRs set from each of a heavy and a light chain V region.
- Framework Regions refer to amino acid sequences interposed between CDRs.
- variable regions of the light and heavy chains typically comprise 4 framework regions and 3 CDRs of the following sequence: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
- residues in antibody variable domains are conventionally numbered according to a system devised by Kabat et al. This system is set forth in Kabat et al., 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (Kabat et al., 1992, hereafter “Kabat et al.”).
- Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues in SEQ ID sequences.
- the actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining region (CDR), of the basic variable domain structure.
- CDR complementarity determining region
- the correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a “standard” Kabat numbered sequence.
- the CDRs of the heavy chain variable domain are located at residues 31- 35 (H-CDR1), residues 50-65 (H-CDR2) and residues 95-102 (H-CDR3) according to the Kabat numbering system.
- the CDRs of the light chain variable domain are located at residues 24-34 (L-CDR1), residues 50-56 (L-CDR2) and residues 89-97 (L-CDR3) according to the Kabat numbering system.
- the CDRs have been determined using CDR finding algorithms from www.bioinf.org.uk - see the section entitled « How to identify the CDRs by looking at a sequence » within the Antibodies pages.
- the term “immunoglobulin domain” refers to a globular region of an antibody chain (such as e.g. a chain of a heavy chain antibody or a light chain), or to a polypeptide that essentially consists of such a globular region.
- Fc region is used to define the C-terminal region of an immunoglobulin heavy chain, including native sequence Fc region and variant Fc regions.
- the human IgG heavy chain Fc region is generally defined as comprising the amino acid residue from position C226 or from P230 to the carboxyl-terminus of the IgG antibody. The numbering of residues in the Fc region is that of the EU index of Kabat.
- the C-terminal lysine (residue K447) of the Fc region may be removed, for example, during production or purification of the antibody.
- composition of antibodies of the invention may comprise antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue.
- the term "chimeric antibody” refers to an antibody which comprises a VH domain and a VL domain of a non-human antibody, and a CH domain and a CL domain of a human antibody.
- a “chimeric antibody” is an antibody molecule in which (a) the constant region (i.e., the heavy and/or light chain), or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, an agonist molecule, e.g., CD40 Ligand, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.
- Chimeric antibodies also include primatized and in particular humanized antibodies. Furthermore, chimeric antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol.2:593- 596 (1992). (see U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
- humanized antibody include antibodies which have the 6 CDRs of a murine antibody, but humanized framework and constant regions. More specifically, the term “humanized antibody”, as used herein, may include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. As used herein the term “human monoclonal antibody”, is intended to include antibodies having variable and constant regions derived from human immunoglobulin sequences.
- the human antibodies of the present invention may include amino acid residues not encoded by human immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
- the term "human monoclonal antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
- the term “immune response” refers to a reaction of the immune system to an antigen in the body of a host, which includes generation of an antigen-specific antibody and/or cellular cytotoxic response.
- the immune response to an initial antigenic exposure is typically, detectable after a lag period of from several days to two weeks; the immune response to subsequent stimulus (secondary immune response) by the same antigen is more rapid than in the case of the primary immune response.
- An immune response to a transgene product may include both humoral (e.g., antibody response) and cellular (e.g., cytolytic T cell response) immune responses that may be elicited to an immunogenic product encoded by the transgene.
- the level of the immune response can be measured by methods known in the art (e.g., by measuring antibody titre).
- APCs or "Antigen Presenting Cells” denotes cells that are capable of activating T-cells, and include, but are not limited to, certain macrophages, B cells and dendritic cells.
- DCs refer to any member of a diverse population of morphologically similar cell types found in lymphoid or non-lymphoid tissues. These cells are characterized by their distinctive morphology, high levels of surface MHC-class II expression (Steinman, et al., Ann. Rev. Immunol. 9:271 (1991); incorporated herein by reference for its description of such cells).
- CD40 has its general meaning in the art and refers to human CD40 polypeptide receptor. In some embodiments, CD40 is the isoform of the human canonical sequence as reported by UniProtKB-P25942 (also referred as human TNR5).
- CD40L has its general meaning in the art and refers to human CD40L polypeptide, for example, as reported by UniProtKB-P25942, including its CD40- binding domain of SEQ ID NO:4. CD40L may be expressed as a soluble polypeptide and is the natural ligand of CD40 receptor.
- CD40 agonist antibody is intended to refer to an antibody that increases CD40 mediated signaling activity in the absence of CD40L in a cell-based assay, such as the B cell proliferation assay.
- the CD40 agonist antibody (i) it induces the proliferation of B cell, as measured in vitro by flow cytometric analysis, or by analysis of replicative dilution of CFSE-labeled cells; and/or (ii) induces the secretion of cytokines, such as IL-6, IL-12, or IL-15, as measured in vitro with a dendritic cell activation assay.
- cytokines such as IL-6, IL-12, or IL-15
- the term “Langerin” has its general meaning in the art and refers to human C- type lectin domain family 4 member K polypeptide.
- Langerin is the isoform of the human canonical sequence as reported by UniProtKB- Q9UJ71 (also referred as human CD207).
- treatment refers to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patient at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
- the treatment may be administered to a patient having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a patient beyond that expected in the absence of such treatment.
- therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
- a therapeutic regimen may include an induction regimen and a maintenance regimen.
- the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
- the general goal of an induction regimen is to provide a high level of drug to a patient during the initial period of a treatment regimen.
- An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
- maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years).
- a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular interval, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., pain, disease manifestation, etc.]).
- the term “pharmaceutical composition” refers to a composition described herein, or pharmaceutically acceptable salts thereof, with other agents such as carriers and/or excipients.
- the pharmaceutical compositions as provided herewith typically include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical-Sciences, Sixteenth Edition, E. W.
- the term “vaccination” or “vaccinating” means, but is not limited to, a process to elicit an immune response in a subject against a particular antigen.
- the term “vaccine composition” is intended to mean a composition which can be administered to humans or to animals in order to induce an immune system response; this immune system response can result in the activation of certain cells, in particular APCs, T lymphocytes and B lymphocytes.
- the term "antigen” refers to a molecule capable of being specifically bound by an antibody or by a T cell receptor (TCR) if processed and presented by MHC molecules.
- An antigen is additionally capable of being recognized by the immune system and/or being capable of inducing a humoral immune response and/or cellular immune response leading to the activation of B- and/or T-lymphocytes.
- An antigen can have one or more epitopes or antigenic sites (B- and T- epitopes).
- adjuvant refers to a compound that can induce and/or enhance the immune response against an antigen when administered to a subject or an animal.
- the term "adjuvant” means a compound, which enhances both innate immune response by affecting the transient reaction of the innate immune response and the more long-lived effects of the adaptive immune response by activation and maturation of the antigen-presenting cells (APCs) especially Dendritic cells (DCs).
- APCs antigen-presenting cells
- DCs Dendritic cells
- therapeutically effective amount is meant a sufficient amount of the active ingredient of the present invention to induce an immune response at a reasonable benefit/risk ratio applicable to the medical treatment.
- the first object of the present invention relates to an antibody that is directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to a polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 “(Niv(G) B ectodomain”).
- the light chain of the antibody is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain).
- the heavy chain of the antibody is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain).
- the heavy chain and/or the light chain of the antibody is conjugated or fused to the Niv(G)B ectodomain via its C-terminal. In some embodiments, the heavy chain and/or the light chain of the antibody is fused to the N-terminal of the Niv(G)B ectodomain. In some embodiments, the heavy chain and/or the light chain of the antibody is conjugated to the Niv(G) B ectodomain by using chemical coupling. Several methods are known in the art for the attachment or conjugation of an antibody to its conjugate moiety.
- linker types that have been used to conjugate a moiety to an antibody include, but are not limited to, hydrazones, thioethers, esters, disulfides and peptide-containing linkers, such as valine-citruline linker.
- a linker can be chosen that is, for example, susceptible to cleavage by low pH within the lysosomal compartment or susceptible to cleavage by proteases, such as proteases preferentially expressed in tumor tissue such as cathepsins (e.g., cathepsins B, C, D).
- the peptide is covalently attached to lysine or cysteine residues on the antibody, through N- hydroxysuccinimide ester or maleimide functionality respectively.
- TDCs cysteine-based site-specific conjugation called ‘‘THIOMABs’’ (TDCs) that are claimed to display an improved therapeutic index as compared to conventional conjugation methods. Conjugation to unnatural amino acids that have been incorporated into the antibody is also being explored for ADCs; however, the generality of this approach is yet to be established (Axup et al., 2012).
- Fc-containing polypeptide engineered with an acyl donor glutamine-containing tag e.g., Gin-containing peptide tags or Q- tags
- an endogenous glutamine that are made reactive by polypeptide engineering (e.g., via amino acid deletion, insertion, substitution, or mutation on the polypeptide).
- a transglutaminase can covalently crosslink with an amine donor agent (e.g., a small molecule comprising or attached to a reactive amine) to form a stable and homogenous population of an engineered Fc-containing polypeptide conjugate with the amine donor agent being site-specifically conjugated to the Fc- containing polypeptide through the acyl donor glutamine-containing tag or the accessible/exposed/reactive endogenous glutamine (WO 2012059882).
- an amine donor agent e.g., a small molecule comprising or attached to a reactive amine
- the heavy chain and/or the light chain of the antibody is conjugated to the Niv(G)B ectodomain by a dockerin domain or multiple domains to permit non-covalent coupling to cohesin fusion proteins as described in US20160031988A1 and US20120039916A1.
- the heavy chain and/or light of the antibody is fused to the Niv(G) B ectodomain to form a fusion protein.
- the Niv(G)B ectodomain is fused either directly or via a linker to the heavy and/or light chain.
- the term "directly" means that the first amino acid at the N-terminal end of the Niv(G)B ectodomain is fused to the last amino acid at the C-terminal end of the heavy or light chain. This direct fusion can occur naturally as described in (Vigneron et al., Science 2004, PMID 15001714), (Warren et al., Science 2006, PMID 16960008), (Berkers et al., J. Immunol.2015a, PMID 26401000), (Berkers et al., J.
- the N-terminal of the Niv(G)B ectodomain is fused to the C-terminal of the heavy chain directly or via a linker.
- the linker is selected from the group consisting of SEQ ID NO:5 (FlexV1), SEQ ID NO:6 (f1), SEQ ID NO:7 (f2), SEQ ID NO:8 (f3), or SEQ ID NO:9 (f4), as described below.
- the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid
- the C-terminal of the light chain of the antibody is conjugated or fused to the N-terminal of the the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F) B ”), and the C- terminal of the heavy chain of the antibody is conjugated or fused to the N-terminal of the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G) B ectodomain).
- the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope- rich peptide Niv(N) B ”).
- the C-terminal of the light chain of the antibody is conjugated or fused to the N-terminal of the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N) B ”) and the C- terminal of the heavy chain of the antibody is conjugated or fused to the N-terminal of the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G) B ectodomain).
- the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to both i) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F) B ”) and ii) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope- rich peptide Niv(N) B ”).
- the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to both a fusion protein wherein i) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N) B ”) is fused to ii) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv
- the light chain is conjugated or fused to a fusion protein comprising the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F) B ”) fused via its C-terminal directly or via a linker to the N-terminal of the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N)B”).
- the light chain of the antibody is conjugated or fused to the fusion protein via its C-terminal.
- the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N)B”) is fused via a linker to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F) B ”).
- the linker consists of the amino acid sequence as set forth in SEQ ID NO:10.
- SEQ ID NO: 10 AEAAAKEAAAKA
- the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G) B ectodomain) and - a light chain is conjugated or fused to both the fusion protein having at least 80% of identity with amino acid sequence as set forth in SEQ ID NO:11.
- the antibody is an IgG antibody, preferably of an IgG1 or IgG4 antibody, or even more preferably of an IgG4 antibody.
- the antibody is a chimeric antibody, in particular a chimeric mouse/human antibody.
- the antibody is humanized antibody. Chimeric or humanized antibodies can be prepared based on the sequence of a murine monoclonal antibody prepared as described above.
- DNA encoding the heavy and light chain immunoglobulins can be obtained from the murine hybridoma of interest and engineered to contain non-murine (e.g., human) immunoglobulin sequences using standard molecular biology techniques.
- the murine variable regions can be linked to human constant regions using methods known in the art (see e.g., U.S. Patent No. 4,816,567 to Cabilly et al.).
- the murine CDR regions can be inserted into a human framework using methods known in the art. See e.g., U.S. Patent No. 5,225,539 to Winter, and U.S. Patent Nos.
- the antibody is a human antibody.
- human antibodies can be identified using transgenic or transchromosomic mice carrying parts of the human immune system rather than the mouse system.
- HuMAb mice ® (Medarex, Inc.) contains human immunoglobulin gene miniloci that encode un-rearranged human heavy ( ⁇ and ⁇ ) and ⁇ light chain immunoglobulin sequences, together with targeted mutations that inactivate the endogenous ⁇ and ⁇ chain loci (see e.g., Lonberg, et al., 1994 Nature 368(6474): 856-859).
- human antibodies can be raised using a mouse that carries human immunoglobulin sequences on transgenes and transchomosomes such as a mouse that carries a human heavy chain transgene and a human light chain transchromosome.
- KM mice a mouse that carries a human heavy chain transgene and a human light chain transchromosome.
- the antibody is specific for a cell surface marker of a professional APC.
- the antibody may be specific for a cell surface marker of another professional APC, such as a B cell or a macrophage.
- the antibody is selected from an antibody that specifically binds to DC immunoreceptor (DCIR), MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CDl lb, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN- ⁇ receptor and IL-2 receptor, ICAM-1, Fey receptor, LOX-1, and ASPGR.
- DCIR DC immunoreceptor
- MHC class I MHC class II
- CD1, CD2, CD3, CD4, CD8, CDl lb CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44
- the antibody is specific for CD40.
- the anti-CD40 antibody derives from the 12E12 antibody and comprises: - a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GFTFSDYYMY (SEQ ID NO:12), the CDR2H having the amino acid sequence YINSGGGSTYYPDTVKG (SEQ ID NO:13), and the CDR3H having the amino acid sequence RGLPFHAMDY (SEQ ID NO:14), - and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence SASQGISNYLN (SEQ ID NO:15) the CDR2L having the amino acid sequence YTSILHS (SEQ ID NO:16) and the CDR3L having the amino acid sequence QQFNKLPPT (SEQ ID NO:17).
- the anti-CD40 antibody derives from the 11B6 antibody and comprises: - a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GYSFTGYYMH (SEQ ID NO:18), the CDR2H having the amino acid sequence RINPYNGATSYNQNFKD (SEQ ID NO:19), and the CDR3H having the amino acid sequence EDYVY (SEQ ID NO:20), and - a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence RSSQSLVHSNGNTYLH (SEQ ID NO:21) the CDR2L having the amino acid sequence KVSNRFS (SEQ ID NO:22) and the CDR3L having the amino acid sequence SQSTHVPWT (SEQ ID NO:23).
- the anti-CD40 antibody derives from the 12B4 antibody and comprises: - a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GYTFTDYVLH (SEQ ID NO:24), the CDR2H having the amino acid sequence YINPYNDGTKYNEKFKG (SEQ ID NO:25), and the CDR3H having the amino acid sequence GYPAYSGYAMDY (SEQ ID NO:26), and - a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence RASQDISNYLN (SEQ ID NO:27) the CDR2L having the amino acid sequence YTSRLHS (SEQ ID NO:28) and the CDR3L having the amino acid sequence HHGNTLPWT (SEQ ID NO:29).
- the anti-CD40 antibody is selected from the group consisting of selected mAb1, mAb2, mAb3, mAb4, mAb5 and mAb6 as described in Table A.
- mAb1 [11B6 SEQ ID NO:30 SEQ ID NO:31 SEQ ID NO:30 (Amino acid sequence of variable heavy chain region (VH) (v2) of Humanized 11B6) EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINPYNGATSYNQNFKDRAT LTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGTTVTVSSAS SEQ ID NO:31 (Amino acid sequence of variable light chain (VL) Vk (v2) of humanized 11B6 VL) DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKVSNRFSGVPDRFSG SGSGTDFTLKISR
- the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:32, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:31. In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:33, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:34. In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the amino acid sequence set forth as SEQ ID NO:35, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:36.
- the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:37, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:38. In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:39, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:40. In some embodiments, the anti-CD40 antibody is a CD40 agonist antibody. CD40 agonist antibodies are described in WO2010/009346, WO2010/104747 and WO2010/104749.
- anti-CD40 agonist antibodies in development include CP-870,893 that is a fully human IgG2 CD40 agonist antibody developed by Pfizer. It binds CD40 with a KD of 3.48 ⁇ 10 ⁇ 10 M, but does not block binding of CD40L (see e.g., U.S. Pat. No. 7,338,660) and SGN-40 that is a humanized IgG1 antibody developed by Seattle Genetics from mouse antibody clone S2C6, which was generated using a human bladder carcinoma cell line as the immunogen.
- the CD40 agonist antibody is selected from the group consisting of selected mAb1, mAb2, mAb3, mAb4, mAb5 and mAb6 as described in Table A.
- the antibody is specific for Langerin.
- the antibody derives from the antibody 15B10 having ATCC Accession No. PTA-9852.
- the antibody derives from the antibody 2G3 having ATCC Accession No. PTA- 9853.
- the antibody derives from the antibody 91E7, 37C1, or 4C7 as described in WO2011032161.
- the anti-Langerin antibody comprises a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H of the 15B10 antibody and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L of the 15B10 antibody.
- the anti-Langerin antibody comprises a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H of the 2G3 antibody and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L of the 2G3 antibody.
- the anti-Langerin antibody comprises a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H of the 4C7 antibody and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L of the 4C7 antibody.
- the antibody is selected from the group consisting of selected mAb7, mAb8 and mAb9, as described in Table B.
- mAb7 SEQ ID NO:41
- SEQ ID NO:42 mAb9
- SEQ ID NO:45 SEQ ID NO:46
- SEQ ID NO:42 Amino acid sequence of variable light chain (VL) 15B10)
- LGLYFCS SEQ ID NO:43 (Amino acid sequence of variable heavy chain region (VH) of
- the anti-Langerin antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:43, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:44. In some embodiments, the anti-Langerin antibody comprises: a heavy chain having the the amino acid sequence set forth as SEQ ID NO:45, and a light chain having a sequence set forth as SEQ ID NO:46.
- the antibodies of the invention may be produced by any technique known per se in the art, such as, without limitation, any chemical, biological, genetic or enzymatic technique, either alone or in combination.
- the antibodies of the invention can be synthesized by recombinant DNA techniques as is now well-known in the art.
- these fragments can be obtained as DNA expression products after incorporation of DNA sequences encoding the desired (poly) peptide into expression vectors and introduction of such vectors into suitable eukaryotic or prokaryotic hosts that will express the desired polypeptide, from which they can be later isolated using well-known techniques.
- the amino acid sequence herein described comprise one or more sequences originating from the restriction cloning site(s) present in the polynucleotide encoding for said amino acid sequence. Typically, said sequences may consist of 2 amino acid residues and typically include AP, AS, AR, PR, SA, TR, and TS sequences. In some embodiments, the amino acid sequences herein described the sequence of a signal peptide. As used herein, the term "signal peptide" has its general meaning in the art and refers to a pre-peptide which is present as an N-terminal peptide on a precursor form of a protein.
- the function of the signal peptide is to facilitate translocation of the expressed polypeptide to which it is attached into the endoplasmic reticulum.
- the signal peptide is normally cleaved off in the course of this process.
- the signal peptide may be heterologous or homologous to the organism used to produce the polypeptide.
- the antibody of the present invention comprises: - a heavy chain having at least 80% of identity with the amino acid sequence as set forth in SEQ ID NO:47, and - a light chain having at least 80% of identity with amino acid sequence as set forth in SEQ ID NO:48.
- a further object of the invention relates to a polynucleotide that encodes for a heavy chain and/or light chain of the antibody of the present invention.
- said polynucleotide is a DNA or RNA molecule, which may be included in any suitable vector, such as a plasmid, cosmid, episome, artificial chromosome, phage or a viral vector.
- a further object of the invention relates to a vector comprising a polynucleotide of the present invention.
- Such vectors may comprise regulatory elements, such as a promoter, enhancer, terminator and the like, to cause or direct expression of said antibody upon administration to a subject.
- promoters and enhancers used in the expression vector for animal cell include early promoter and enhancer of SV40, LTR promoter and enhancer of Moloney mouse leukemia virus, promoter and enhancer of immunoglobulin H chain and the like. Any expression vector for animal cell can be used, so long as a gene encoding the human antibody C region can be inserted and expressed. Examples of suitable vectors include pAGE107, pAGE103, pHSG274, pKCR, pSG1 beta d2-4 and the like. Other examples of plasmids include replicating plasmids comprising an origin of replication, or integrative plasmids, such as for instance pUC, pcDNA, pBR, and the like.
- viral vector examples include adenoviral, retroviral, herpes virus and AAV vectors.
- recombinant viruses may be produced by techniques known in the art, such as by transfecting packaging cells or by transient transfection with helper plasmids or viruses.
- Typical examples of virus packaging cells include PA317 cells, PsiCRIP cells, GPenv+ cells, 293 cells, etc.
- Detailed protocols for producing such replication- defective recombinant viruses may be found for instance in WO 95/14785, WO 96/22378, US 5,882,877, US 6,013,516, US 4,861,719, US 5,278,056 and WO 94/19478.
- a further object of the present invention relates to a host cell which has been transfected, infected or transformed by a polynucleotide and/or a vector according to the invention.
- the polynucleotides of the invention may be used to produce an antibody of the present invention in a suitable expression system.
- Common expression systems include E. coli host cells and plasmid vectors, insect host cells and Baculovirus vectors, and mammalian host cells and vectors.
- Other examples of host cells include, without limitation, prokaryotic cells (such as bacteria) and eukaryotic cells (such as yeast cells, mammalian cells, insect cells, plant cells, etc.). Specific examples include E.coli, Kluyveromyces or Saccharomyces yeasts.
- Mammalian host cells include Chinese Hamster Ovary (CHO cells) including dhfr- CHO cells (described in Urlaub and Chasin, 1980) used with a DHFR selectable marker, CHOK1 dhfr+ cell lines, NSO myeloma cells, COS cells and SP2 cells, for example GS CHO cell lines together with GS Xceed TM gene expression system (Lonza), or HEK cells.
- CHO cells Chinese Hamster Ovary (CHO cells) including dhfr- CHO cells (described in Urlaub and Chasin, 1980) used with a DHFR selectable marker, CHOK1 dhfr+ cell lines, NSO myeloma cells, COS cells and SP2 cells, for example GS CHO cell lines together with GS Xceed TM gene expression system (Lonza), or HEK cells.
- the present invention also relates to a method of producing a recombinant host cell expressing the antibody according to the invention, said method comprising the steps of: (i) introducing in vitro or ex vivo a recombinant polynucleotide or a vector as described above into a competent host cell, (ii) culturing in vitro or ex vivo the recombinant host cell obtained and (iii), optionally, selecting the cells which express and/or secrete said antibody.
- Such recombinant host cells can be used for the production of antibodies of the present invention.
- the host cell as disclosed herein are thus particularly suitable for producing the antibody of the present invention.
- the polypeptides are produced by culturing the host cells for a period of time sufficient for expression of the antibody in the host cells and, optionally, secretion of the antibody into the culture medium in which the host cells are grown.
- the antibodies can be recovered and purified for example from the culture medium after their secretion using standard protein purification methods.
- Pharmaceutical and vaccine compositions The antibodies as described herein may be administered as part of one or more pharmaceutical compositions. Except insofar as any conventional carrier medium is incompatible with the antibodies of the present invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.
- materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as
- the antibodies as described herein are particularly suitable for preparing vaccine composition.
- a further object of the present invention relates to a vaccine composition comprising an antibody of the present invention.
- the vaccine composition of the present invention comprises an adjuvant.
- the adjuvant is alum.
- the adjuvant is Incomplete Freund’s adjuvant (IFA) or other oil based adjuvant that is present between 30-70%, preferably between 40-60%, more preferably between 45-55% proportion weight by weight (w/w).
- the adjuvant is Polyinosinic-polycytidylic acid (poly (I:C)) or Polyinosinic- Polycytidylic acid – poly-L-lysine carboxymethylcellulose (Poly-ICLC).
- the vaccine composition of the present invention comprises at least one Toll- Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists.
- TLR Toll- Like Receptor
- Therapeutic methods The antibodies as well as the pharmaceutical or vaccine compositions as herein described are particularly suitable for inducing an immune response against Nipah virus and thus can be used for vaccine purposes.
- a further object of the present invention relates to a method for vaccinating a subject in need thereof against Nipah virus comprising administering a therapeutically effective amount of the antibody of the present invention.
- the antibodies as well as the pharmaceutical or vaccine compositions as herein described are particularly suitable for the treatment of Nipah virus infection.
- the subject can be human or any other animal (e.g., birds and mammals) susceptible to Nipah virus infection (e.g., domestic animals such as cats and dogs; livestock and farm animals such as horses, cows, pigs, chickens, etc.).
- said subject is a mammal including a non-primate (e.g., a camel, donkey, zebra, cow, pig, horse, goat, sheep, cat, dog, rat, and mouse) and a primate (e.g., a monkey, chimpanzee, and a human).
- a non-primate e.g., a camel, donkey, zebra, cow, pig, horse, goat, sheep, cat, dog, rat, and mouse
- a primate e.g., a monkey, chimpanzee, and a human
- the subject is a non-human animal.
- the subject is a farm animal or pet.
- the subject is a human.
- the subject is a human infant.
- the subject is a human child.
- the subject is a human adult.
- the subject is an elderly human.
- the subject is a premature human infant.
- the subject can be symptomatic or asymptomatic.
- the active ingredient of the present invention i.e., the antibodies and the pharmaceutical or vaccine compositions as herein described
- the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts.
- the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
- compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
- a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, in particular from 1 mg to about 100 mg of the active ingredient.
- An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
- the antibodies and the pharmaceutical or vaccine compositions as herein described may be administered to the subject by any route of administration and in particular by oral, nasal, rectal, topical, buccal (e.g., sub-lingual), parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active agent which is being used.
- the invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
- FIGURES Figure 1. Epitope mapping of NiV G antigen associated to the CD40 mAb.
- FIG. 1 Schematic representation of Generation 1 (Gen-1) and Generation 2 (Gen-2) vaccines.
- Figure 4 Gen-1, Gen-2 and IgG4 control vaccine SDS PAGE profiles in non-reduced (NR) versus reduced (R) conditions.
- Figure 5 The G antigen fused to Gen-1 vaccine was confirmed by Western-Blot, using sera from Niv(G)-immunized mice and testing the in-house produced G protein as positive control. Molecular weight (kDa) markers are shown in the left lane. Arrows indicate the heavy chain (HC) and light chain (LC) of the vaccine constructions at the expected size, respectively.
- Figure 6 Size exclusion chromatography (SEC) of Gen-1 and Gen-2 vaccines with standard proteins size markers. Recombinant mAb are indicated by arrows.
- Figure 7 Binding assay of CD40.NiV vaccines to mouse cells expressing the human CD40 receptor.
- Mouse splenocytes from hCD40 My/Hu Tg mice were incubated with 10nM of CD40.Niv Gen-1 mAbs and subsequently labeled for T-, B and DC cell markers, respectively. Untreated and splenocytes treated with the non-targeting IgG4.Niv were used as negative controls.
- Figure 8 Binding assay of CD40.NiV vaccines to AGM PBMCs. Same method as Fig-7, using PBMCs from na ⁇ ve AGM.
- Niv(G)-specific B cells are considered double positive for the two anti-Biotin mAbs.
- Figure 13 Gen-1 and -2 CD40.NiV vaccines induced cellular immune responses in hCD40 Hy/Mu transgenic mice.
- IFN-g T cells responses to the G, F and N overlapping pools of peptides were assessed by ELISpot, one week post boost.
- Bottom right Percentages of G, F and N-specific responses, at 10 and 30ug of vaccine, respectively. Plain circle, with Poly-ICLC, open circles, without Poly-ICLC.
- Figure 15 As in Figure 10, neutralization activity of AGM sera was measured by indirect inhibition assay
- Figure 16 In vitro neutralization of NiV-B by sera from vaccinated AGM.
- Figure 17 As in Fig-13, total specific IFN- ⁇ responses to the G, F and N antigens were measured in AGM circulating PBMCs collected at day 21 and 35 post-immunization. Number of spots are reported per million of PBMC. Pointed line represents threshold for positivity defined by the mean responses (+3SD) of the non-vaccinated AGM group. (right) Percentage (%) of specific T cell response to each vaccine antigen (mean ⁇ SD).
- Figure 19 Protection assay in AGM. Survival curve. Nine AGM were immunized twice with CD40.NiV (Gen-2) and challenged with 10 2 Pfu NiV-B (intratracheal route). Height na ⁇ ve animals were used as controls. Gehan-Breslow-Wilcoxon test, ****, p ⁇ 0.0001.
- Figure 20 Clinical scores and temperatures of na ⁇ ve (black circle) and vaccinated AGMs (white circle). Dotted line score threshold for ethical considerations (left panel); dotted line: median temperature at day 0 (right panel).
- Figure 21 Viral dissemination post-challenge.
- A (left) Amount of viral NiV RNA quantified by RT-PCR (N gene) in PBLs. Values were normalized against those of the GADPH housekeeping gene. Genomic RNA was measured by RT-qPCR in nasal (middle) and pharyngeal (right) swabs.
- Gen1 vaccine was assessed by western blot ( Figure 5), using sera from C57BL/6 mice immunized by the in-house produced G protein (+CpG). The H-chain fused with the G protein was revealed by the mouse sera. Binding assay: Gen-1 antibodies and same 12E12/VH3 clone without any antigen were marked by a fluorochrome. The clone 11B6 was also tested in parallel as positive control. Mouse splenocytes from hCD40 Tg mice ( Figure 7) and PBMCs from AGM ( Figure 8) were incubated with fluorescent vaccine in vitro. Cells were phenotyped and analyzed by FACS.
- Virology RNA extraction from infected AGM PBL Blood samples from infected AGMs collected in EDTA tubes were diluted in Pharmalyse buffer, vortexed, and incubated in the dark for 15 min. They were then centrifuged at 200 x g for 5 min and the pellets washed in 2 mL PBS 1% FBS, 2 mM EDTA. Finally, pellets were resuspended in 600 ⁇ L RLT lysis buffer and purified following the manufacturer’s instructions (Macherey Nagel). Samples were stored at -80°C till use.
- RT-qPCR Viral RNA was extracted using a Qiamp Viral RNA Kit (Qiagen) for serum, swabs, urine, BAL, vitreous humor, and thoracic exudate samples and a Nucleospin Kit (Macherey Nagel) for PBMCs and organs. Viral load was evaluated by one-step RT-qPCR using NiV-N-specific primers and GAPDH primers, if necessary ( Figure 21). Results: In silico down-selection of NiV predictive immunogenic peptides and CD40.NiV vaccine design Two CD40.NiV vaccine candidates have been successfully produced.
- Gen-2 vaccine is also associated with in silico down selected peptides from the F and N proteins, and that are predicted to be enriched in T- and B-cells epitopes ( Figures 1 to 8).
- the NiV surface glycoprotein (G) is a gold-standard antigen for inducing protective humoral responses.
- Other cellular effectors, such as helper and effector T-cells, may also participate in host defense.
- NiV G ectodomain ECD
- NetMHC 4.0 and NetMHCII 2.3 software which predict T-cell epitopes that bind to a large panel of class-I and -II HLA molecules, respectively.
- Linear B-cell epitopes were predicted using BepiPred 2.0.
- the NiV G ECD vaccine region was predicted to contain 3522 and 15 T- and B-cell epitopes, respectively. Due to their conservation between NiV strains, we further identified vaccine epitopes from the fusion (F) and nucleocapsid (N) proteins. Regions with strong binder epitopes and the highest HLA coverage were highlighted, as well as linear B-cell epitopes.
- NiV F and NiV N (aa 318-355) down-selected peptides contain 356 and 266 predicted T- cell epitopes and three and linear B-cell epitopes, respectively. Globally, these amino acid sequences were screened for homology with other Henipaviruses, obtaining 100% homology between different Nipah strains for the F and N peptides and more than 98% for NiV G ECD.
- CD40.NiV splenocytes from mice transgenic for the human CD40 receptor (CD40Hy/Mu transgenic mice; hCD40Tg) and PBMCs from AGM, respectively ( Figure 7-8)
- CD40.NiV induces specific T- and B-cell responses in hCD40Tg mice
- hCD40Tg mice were immunized with two subcutaneous (SC) injections of CD40.NiV (Gen-1 or Gen-2) vaccine (10 ⁇ g) or an equivalent amount of NiV G protein, both with poly-ICLC (50 ⁇ g) on days 0 and 21.
- Antibody-mediated immune responses were first evaluated by Luminex assay.
- Our results showed a significant G-specific IgG titer with both vaccines (Figure 9).
- Three weeks post- prime, mice immunized with the CD40-targeted NiV G protein showed significantly higher anti-NiV G IgG levels (P ⁇ 0.01), highlighting the benefit conferred by the DC-targeting system.
- the CD40.NiV vaccine induces early and robust humoral and T-cell responses in AGMs
- AGM African Green Monkey
- Twelve animals have been imported and housed at the Bioprim animal center (Toulouse).
- Two groups of animals have been immunized in a prime-boost homologous regimen, as follow: 3 AGM with Poly-ICLC alone versus 9 AGM with 200ug of Gen-2 vaccine + Poly-ICLC.
- Vaccination elicited a neutralization potential of NiV G-specific IgG by day 10 post-prime, reaching significance two weeks post-boost (mean neutralization titer 3.2 ( ⁇ 0.2), P ⁇ 0.001), and remained high until day 56 ( Figures 15, 16 and 18).
- the neutralizing capacity of specific antibodies was confirmed post-prime and post-boost using the Luminex-based surrogate inhibition assay (P ⁇ 0.001) (data not shown).
- Enzyme activity levels (aspartate aminotransferase, AST; creatine kinase, CK) reflecting hepatic disorders were above normal values during the critical disease period for controls but not the vaccinated animals.
- NiV viremia Plasma and tissue viral loads in challenged AGMs
- NiV-B replication in nasal and nasopharyngeal swabs, fluids, including broncho-alveolar lavages (BALs), sera, urine, and thoracic exudates, and organs (lung, spleen, and neurological tissue) was undetectable in immunized AGMs, whereas it was detected at high levels in controls ( Figure 21B). This strong antiviral effect was confirmed by the lack of expression of the NiV N protein in tissues of the lungs and spleen, as assessed by histo-immunofluorescence (data not shown).
- Viral syncytia were detected in the lungs of non-immunized animals. Of note, NiV-B infection of the brain could not be confirmed by histo-immunofluorescence. Overall, CD40.NiV (Gen-2) vaccination led to sterilizing immunity that limited viral propagation, as well as viral shedding, in AGMs. Immunological and cytokine features of challenged animals We further characterized the post-challenge immune responses by immunological phenotyping of the cell populations from 0 to 22 dpc. The succumbing animals showed profound and significant defects in the lymphoid populations (CD20+ B- and CD3+ T-cells) (data not shown).
- the DC-targeting strategy allowed us to design a subunit construct containing immunogenic and cross-reactive epitopes from the F and N NiV proteins, in addition to the NiV G ECD, in contrast to most other NiV vaccine platforms (Bossart et al., 2012; Foster et al., 2022; Geisbert et al., 2021; 287 Loomis et al., 2020; Mohammed et al., 2020; Woolsey et al., 2023; Yoneda et al., 2013).
- the CD40.NiV vaccine induced both IgG and IgA antibodies as early as 10 days post-prime in AGMs. We also show that neutralizing responses can be maintained, with a stable estimated mean log titer of approximately 2.2 ( ⁇ 0.1) 100 days after the peak of the Ab response. Responses were showed to cross-neutralize multiple strains of NiV, but also HeV. Although detectable at a lower level, we found that the CD40.NiV vaccine elicited a T-cell response against the NiV G ECD and down-selected F and N peptides in two preclinical models.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus. The inventors now designed an anti-CD40 mAb associated either with the Niv G ectodomain protein (Generation-1 vaccine), or the Niv G ectodomain protein and down-selected epitopes from the Niv F and N proteins (Generation-2 vaccine). Quality controls were performed on vaccine batches. The immunogenicity of both vaccines has been tested in hCD40Tg mice. A dose- dependent IFNg T cell response to the antigen was observed. Three weeks post-boost, specific IgG were detectable in groups immunized with 10ug of vaccine. B cell responses were markedly improved 1 week post-boost. All samples at week -4 showed a neutralization with an average titer at 1:500. The inventors also demonstrated the potency of an innovative DC- targeting vaccine candidate to prevent NiV-B infection in challenge experiments in an AGM model. Responses were showed to cross-neutralize multiple strains of NiV, but also HeV. Targeting Nipah virus antigens to professional APCs can be efficiently used as a prophylactic means against a Nipah virus challenge at a lethal dose. Accordingly, the present invention relates to antibodies that are directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to the Nipah virus antigenic polypeptides.
Description
DC-TARGETING VACCINE AGAINST NIPAH VIRUS INFECTION FIELD OF THE INVENTION: The present invention is in the field of medicine, in particular virology. BACKGROUND OF THE INVENTION: Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus first recognized following a 1998-99 outbreak of severe febrile encephalitis in Malaysia and Singapore (Chua, K. B., et al. "Nipah virus: a recently emergent deadly paramyxovirus." Science 288.5470 (2000): 1432-1435.). The Bangladesh strain (NiVB) has caused repeated outbreaks, varying in number, in Bangladesh and northeast India with outbreaks occurring almost every year between 2001–2015. The outbreaks of NiVB have had high case fatality rate averaging about 75% (Lo, Michael K., et al. "Characterization of Nipah virus from outbreaks in Bangladesh, 2008–2010." Emerging infectious diseases 18.2 (2012): 248.) with human-to- human transmission often observed (Gurley, Emily S., et al. "Person-to-person transmission of Nipah virus in a Bangladeshi community." Emerging infectious diseases 13.7 (2007): 1031.). Multiple candidate vaccines exist, but all are in the preclinical stages. Although rVSV vectors expressing Nipah virus G (or F) are prime candidates for new ‘emergency vaccines’ to be utilized for outbreak management (Foster, Stephanie L., et al. "A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease." Proceedings of the National Academy of Sciences 119.12 (2022): e2200065119.), concerns remain about safety, development and inadequate transport/storage in affected areas. Thus, improving the ability of vaccines to induce strong, cellular and humoral immune responses, placing them as a new generic vaccine platform for prophylactic strategies but also at the heart of a therapeutic arsenal remains the challenge to rapidly and efficiently respond to Nipah. SUMMARY OF THE INVENTION: The present invention is defined by the claims. In particular, the present invention relates to antibodies that are directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to the Nipah virus antigenic polypeptides.
DETAILED DESCRIPTION OF THE INVENTION: Definitions: As used herein, the term "subject" or "subject in need thereof", is intended for a human or non-human mammal. Typically the patient is affected or likely to be infected with Nipah virus. As used herein, the term “Nipah virus” has its general meaning in the art and refers to a virus that is a member of the Paramyxoviridae family and is related to the Hendra virus (formerly called equine morbillivirus). The Nipah virus was initially isolated in 1999 upon examining samples from an outbreak of encephalitis and respiratory illness among adult men in Malaysia and Singapore (see, e.g., Chua et al., Lancet. October 9, 1999;354(9186):1257-9 and Paton et al., Lancet. October 9, 1999;354(9186):1253-6). The host for Nipah virus is still unknown, but flying foxes (bats of the Pteropus genus) are suspected to be the natural host. The Nipah virus comprises a 6-gene, 18.2-kb, negative-sense single-stranded RNA (ssRNA) genome, which encodes 9 proteins: nucleoprotein (N), phosphoprotein (P), the interferon antagonists W and V, the viral C protein, a matrix protein (M), viral fusion and glycoproteins (F and G, respectively), and a large polymerase (L). As used herein, the terms “polypeptide”, “peptide”, and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, phosphorylation, or conjugation with a labeling component. Polypeptides when discussed in the context of gene therapy refer to the respective intact polypeptide, or any fragment or genetically engineered derivative thereof, which retains the desired biochemical function of the intact protein. As used herein, the term “G protein” refers to the Nipah virus glycoprotein G. The G protein has a globular head domain formed of a six-bladed beta sheet-propeller, connected via a flexible stalk domain to a transmembrane anchor. The G protein binds to the cellular receptors ephrin B2 and ephrin B3, mediating viral attachment. Following attachment Nipah Virus glycoprotein G undergoes a conformational change that leads to triggering of glycoprotein F which leads to membrane fusion. An exemplary amino acid sequence for the G protein is represented by SEQ ID NO:1.
SEQ ID NO:1 >sp|Q9IH62|GLYCP_NIPAV Glycoprotein G OS=Nipah virus OX=121791 GN=G PE=1 SV=1
LVGLPNNICLQKTSNQILKPKLISYTLPVVGQSGTCITDPLLAMDEGYFAYSHLERIGSC SRGVSKQRIIGVGEVLDRGDEVPSLFMTNVWTPPNPNTVYHCSAVYNNEFYYVLCAVSTV GDPILNSTYWSGSLMMTRLAVKPKSNGGGYNQHQLALRSIEKGRYDKVMPYGPSGIKQGD TLYFPAVGFLVRTEFKYNDSNCPITKCQYSKPENCRLSMGIRPNSHYILRSGLLKYNLSD GENPKVVFIEISDQRLSIGSPSKIYDSLGQPVFYQASFSWDTMIKFGDVLTVNPLVVNWR NNTVISRPGQSQCPRFNTCPEICWEGVYNDAFLIDRINWISAGVFLDSNQTAENPVFTVF KDNEILYRAQLASEDTNAQKTITNCFLLKNKIWCISLVEIYDTGDNVIRPKLFAVKIPEQ CT As used herein, the term “F protein” refers to the Nipah virus glycoprotein F. Nipah virus glycoprotein F is a class I fusion protein, with typical structural features. These include heptad repeats and a hydrophobic fusion peptide that bind to each other, forming a six-helix bundle which functions in membrane fusion processes. Nipah Virus attaches to target cells via glycoprotein G, which then undergoes a conformational change leading to triggering of Nipah virus glycoprotein F which leads to membrane fusion. An exemplary amino acid sequence for the F protein is represented by SEQ ID NO:2. SEQ ID NO:2 >sp|Q9IH63|FUS_NIPAV Fusion glycoprotein F0 OS=Nipah virus OX=121791 GN=F PE=1 SV=1 MVVILDKRCYCNLLILILMISECSVGILHYEKLSKIGLVKGVTRKYKIKSNPLTKDIVIK MIPNVSNMSQCTGSVMENYKTRLNGILTPIKGALEIYKNNTHDLVGDVRLAGVIMAGVAI GIATAAQITAGVALYEAMKNADNINKLKSSIESTNEAVVKLQETAEKTVYVLTALQDYIN TNLVPTIDKISCKQTELSLDLALSKYLSDLLFVFGPNLQDPVSNSMTIQAISQAFGGNYE TLLRTLGYATEDFDDLLESDSITGQIIYVDLSSYYIIVRVYFPILTEIQQAYIQELLPVS FNNDNSEWISIVPNFILVRNTLISNIEIGFCLITKRSVICNQDYATPMTNNMRECLTGST EKCPRELVVSSHVPRFALSNGVLFANCISVTCQCQTTGRAISQSGEQTLLMIDNTTCPTA VLGNVIISLGKYLGSVNYNSEGIAIGPPVFTDKVDISSQISSMNQSLQQSKDYIKEAQRL LDTVNPSLISMLSMIILYVLSIASLCIGLITFISFIIVEKKRNTYSRLEDRRVRPTSSGD LYYIGT As used herein, the term “N protein” refers to the Nipah virus nucleoprotein that encapsidates the genome protecting it from nucleases. The encapsidated genomic RNA is termed the nucleocapsid (NC) and serves as template for transcription and replication. An exemplary amino acid sequence for the N protein is represented by SEQ ID NO:3. SEQ ID NO:3 >sp|Q9IK92|NCAP_NIPAV Nucleoprotein OS=Nipah virus OX=121791 GN=N PE=1 SV=1
TAPDTAEESETRRWAKYVQQKRVNPFFALTQQWLTEMRNLLSQSLSVRKFMVEILIEVKK GGSAKGRAVEIISDIGNYVEETGMAGFFATIRFGLETRYPALALNEFQSDLNTIKSLMLL YREIGPRAPYMVLLEESIQTKFAPGGYPLLWSFAMGVATTIDRSMGALNINRGYLEPMYF RLGQKSARHHAGGIDQNMANRLGLSSDQVAELAAAVQETSAGRQESNVQAREAKFAAGGV
LIGGSDQDIDEGEEPIEQSGRQSVTFKREMSISSLANSVPSSSVSTSGGTRLTNSLLNLR SRLAAKAAKEAASSNATDDPAISNRTQGESEKKNNQDLKPAQNDLDFVRADV As used herein, the term “polynucleotide” refers to a polymeric form of nucleotides of any length, including deoxyribonucleotides or ribonucleotides, or analogs thereof. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, and may be interrupted by non-nucleotide components. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The term polynucleotide, as used herein, refers interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form. As used herein, the expression “derived from” refers to a process whereby a first component (e.g., a first polypeptide), or information from that first component, is used to isolate, derive or make a different second component (e.g., a second polypeptide that is different from the first one). As used herein, the term "encoding" refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as, for example, a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (e.g., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene, cDNA, or RNA, encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA. Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase “nucleotide sequence that encodes a protein or a RNA” may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).
As used herein, the terms "vector", "cloning vector" and "expression vector" mean the vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence. As used herein, the term “promoter/regulatory sequence” refers to a polynucleotide sequence (such as, for example, a DNA sequence) recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence, thereby allowing the expression of a gene product operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product. The promoter/regulatory sequence may, for example, be one which expresses the gene product in a tissue specific manner. As used herein, the term "operably linked" or "transcriptional control" refers to functional linkage between a regulatory sequence and a heterologous polynucleotide sequence resulting in expression of the latter. For example, a first polynucleotide sequence is operably linked with a second polynucleotide sequence when the first polynucleotide sequence is placed in a functional relationship with the second polynucleotide sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences can be contiguous with each other and, e.g., where necessary to join two protein coding regions, are in the same reading frame. As used herein, the term "transformation" means the introduction of a "foreign" (i.e., extrinsic or extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell will express the introduced gene or sequence to produce a desired substance, typically a protein or enzyme coded by the introduced gene or sequence. A host cell that receives and expresses introduced DNA or RNA bas been "transformed". As used herein, the term "expression system" means a host cell and compatible vector under suitable conditions, e.g., for the expression of a protein coded for by foreign DNA carried by the vector and introduced to the host cell.
As used herein, the “percent identity” between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions/total number of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described below. The percent identity between two amino acid sequences can be determined using the Needleman and Wunsch algorithm (Needleman, Saul B. & Wunsch, Christian D. (1970). "A general method applicable to the search for similarities in the amino acid sequence of two proteins". Journal of Molecular Biology.48 (3): 443–53.). The percent identity between two nucleotide or amino acid sequences may also be determined using for example algorithms such as EMBOSS Needle (pair wise alignment; available at www.ebi.ac.uk). For example, EMBOSS Needle may be used with a BLOSUM62 matrix, a “gap open penalty” of 10, a “gap extend penalty” of 0.5, a false “end gap penalty”, an “end gap open penalty” of 10 and an “end gap extend penalty” of 0.5. In general, the “percent identity” is a function of the number of matching positions divided by the number of positions compared and multiplied by 100. For instance, if 6 out of 10 sequence positions are identical between the two compared sequences after alignment, then the identity is 60%. The % identity is typically determined over the whole length of the query sequence on which the analysis is performed. Two molecules having the same primary amino acid sequence or polynucleotide sequence are identical irrespective of any chemical and/or biological modification. According to the invention a first amino acid sequence having at least 80% of identity with a second amino acid sequence means that the first sequence has 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99 or 100% of identity with the second amino acid sequence. As used herein, the term “conjugate” or interchangeably “conjugated polypeptide” is intended to indicate a composite or chimeric molecule formed by the covalent attachment of one or more polypeptides. The term “covalent attachment” “or “conjugation” means that the polypeptide and the non-peptide moiety are either directly covalently joined to one another, or else are indirectly covalently joined to one another through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties. A particular conjugate is a fusion protein.
As used herein, the term “fusion protein" indicates a protein created through the attaching of two or more polypeptides which originated from separate proteins. In particular fusion proteins can be created by recombinant DNA technology and are typically used in biological research or therapeutics. Fusion proteins can also be created through chemical covalent conjugation with or without a linker between the polypeptides portion of the fusion proteins. In the fusion protein the two or more polypeptide are fused directly or via a linker. As used herein, the term "directly" means that the first amino acid at the N-terminal end of a first polypeptide is fused to the last amino acid at the C-terminal end of a second polypeptide. This direct fusion can occur naturally as described in (Vigneron et al., Science 2004, PMID 15001714), (Warren et al., Science 2006, PMID 16960008), (Berkers et al., J. Immunol.2015a, PMID 26401000), (Berkers et al., J. Immunol.2015b, PMID 26401003), (Delong et al., Science 2016, PMID 26912858) (Liepe et al., Science 2016, PMID 27846572), (Babon et al., Nat. Med. 2016, PMID 27798614). As used herein, the term “linker” has its general meaning in the art and refers to an amino acid sequence of a length sufficient to ensure that the proteins form proper secondary and tertiary structures. In some embodiments, the linker is a peptidic linker which comprises at least one, but less than 30 amino acids e.g., a peptidic linker of 2-30 amino acids, preferably of 10-30 amino acids, more preferably of 15-30 amino acids, still more preferably of 19-27 amino acids, most preferably of 20-26 amino acids. In some embodiments, the linker has 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30 amino acid residues. Typically, linkers are those which allow the compound to adopt a proper conformation. The most suitable linker sequences (1) will adopt a flexible extended conformation, (2) will not exhibit a propensity for developing ordered secondary structure which could interact with the functional domains of fusion proteins, and (3) will have minimal hydrophobic or charged character which could promote interaction with the functional protein domains. As used herein, the term "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds to an antigen. In natural antibodies of rodents and primates, two heavy chains are linked to each other by disulfide bonds, and each heavy chain is linked to a light chain by a disulfide bond. There are two types of light chains, lambda (1) and kappa (k).
There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each chain contains distinct sequence domains. In typical IgG antibodies, the light chain includes two domains, a variable domain (VL) and a constant domain (CL). The heavy chain includes four domains, a variable domain (VH) and three constant domains (CH1, CH2 and CH3, collectively referred to as CH). The variable regions of both light (VL) and heavy (VH) chains determine binding recognition and specificity to the antigen. The constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans- placental mobility, complement binding, and binding to Fc receptors (FcR). The Fv fragment is the N-terminal part of the Fab fragment of an immunoglobulin and consists of the variable portions of one light chain and one heavy chain. The specificity of the antibody resides in the structural complementarity between the antibody combining site and the antigenic determinant. Antibody combining sites are made up of residues that are primarily from the hypervariable or complementarity determining regions (CDRs). Occasionally, residues from non-hypervariable or framework regions (FR) can participate in the antibody binding site, or influence the overall domain structure and hence the combining site. Complementarity Determining Regions or CDRs refer to amino acid sequences that together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site. The light and heavy chains of an immunoglobulin each have three CDRs, designated L-CDR1, L-CDR2, L- CDR3 and H- CDR1, H-CDR2, H-CDR3, respectively. An antigen-binding site, therefore, typically includes six CDRs, comprising the CDRs set from each of a heavy and a light chain V region. Framework Regions (FRs) refer to amino acid sequences interposed between CDRs. Accordingly, the variable regions of the light and heavy chains typically comprise 4 framework regions and 3 CDRs of the following sequence: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The residues in antibody variable domains are conventionally numbered according to a system devised by Kabat et al. This system is set forth in Kabat et al., 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (Kabat et al., 1992, hereafter “Kabat et al.”). The Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues in SEQ ID sequences. The actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining region (CDR), of the basic variable domain structure. The correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a “standard” Kabat
numbered sequence. The CDRs of the heavy chain variable domain are located at residues 31- 35 (H-CDR1), residues 50-65 (H-CDR2) and residues 95-102 (H-CDR3) according to the Kabat numbering system. The CDRs of the light chain variable domain are located at residues 24-34 (L-CDR1), residues 50-56 (L-CDR2) and residues 89-97 (L-CDR3) according to the Kabat numbering system. For the agonist antibodies described hereafter, the CDRs have been determined using CDR finding algorithms from www.bioinf.org.uk - see the section entitled « How to identify the CDRs by looking at a sequence » within the Antibodies pages. As used herein, the term “immunoglobulin domain” refers to a globular region of an antibody chain (such as e.g. a chain of a heavy chain antibody or a light chain), or to a polypeptide that essentially consists of such a globular region. As used herein, the term “Fc region” is used to define the C-terminal region of an immunoglobulin heavy chain, including native sequence Fc region and variant Fc regions. The human IgG heavy chain Fc region is generally defined as comprising the amino acid residue from position C226 or from P230 to the carboxyl-terminus of the IgG antibody. The numbering of residues in the Fc region is that of the EU index of Kabat. The C-terminal lysine (residue K447) of the Fc region may be removed, for example, during production or purification of the antibody. Accordingly, a composition of antibodies of the invention may comprise antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue. As used herein, the term "chimeric antibody" refers to an antibody which comprises a VH domain and a VL domain of a non-human antibody, and a CH domain and a CL domain of a human antibody. In one embodiment, a “chimeric antibody” is an antibody molecule in which (a) the constant region (i.e., the heavy and/or light chain), or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, an agonist molecule, e.g., CD40 Ligand, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity. Chimeric antibodies also include primatized and in particular humanized antibodies. Furthermore, chimeric antibodies may comprise residues that
are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol.2:593- 596 (1992). (see U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). As used herein, the term “humanized antibody” include antibodies which have the 6 CDRs of a murine antibody, but humanized framework and constant regions. More specifically, the term "humanized antibody", as used herein, may include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. As used herein the term "human monoclonal antibody", is intended to include antibodies having variable and constant regions derived from human immunoglobulin sequences. The human antibodies of the present invention may include amino acid residues not encoded by human immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, in one embodiment, the term "human monoclonal antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. As used herein, the term “immune response” refers to a reaction of the immune system to an antigen in the body of a host, which includes generation of an antigen-specific antibody and/or cellular cytotoxic response. The immune response to an initial antigenic exposure (primary immune response) is typically, detectable after a lag period of from several days to two weeks; the immune response to subsequent stimulus (secondary immune response) by the same antigen is more rapid than in the case of the primary immune response. An immune response to a transgene product may include both humoral (e.g., antibody response) and cellular (e.g., cytolytic T cell response) immune responses that may be elicited to an immunogenic product encoded by the transgene. The level of the immune response can be measured by methods known in the art (e.g., by measuring antibody titre).
As used herein the term “APCs” or "Antigen Presenting Cells" denotes cells that are capable of activating T-cells, and include, but are not limited to, certain macrophages, B cells and dendritic cells. As used herein, the term "Dendritic cells" or “DCs” refer to any member of a diverse population of morphologically similar cell types found in lymphoid or non-lymphoid tissues. These cells are characterized by their distinctive morphology, high levels of surface MHC-class II expression (Steinman, et al., Ann. Rev. Immunol. 9:271 (1991); incorporated herein by reference for its description of such cells). As used herein, the term “CD40” has its general meaning in the art and refers to human CD40 polypeptide receptor. In some embodiments, CD40 is the isoform of the human canonical sequence as reported by UniProtKB-P25942 (also referred as human TNR5). As used herein, the term “CD40L” has its general meaning in the art and refers to human CD40L polypeptide, for example, as reported by UniProtKB-P25942, including its CD40- binding domain of SEQ ID NO:4. CD40L may be expressed as a soluble polypeptide and is the natural ligand of CD40 receptor. SEQ ID NO:4>CD40L binding domain MQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNR EASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHG TGFTSFGLLKL As used herein, the term “CD40 agonist antibody” is intended to refer to an antibody that increases CD40 mediated signaling activity in the absence of CD40L in a cell-based assay, such as the B cell proliferation assay. In particular, the CD40 agonist antibody (i) it induces the proliferation of B cell, as measured in vitro by flow cytometric analysis, or by analysis of replicative dilution of CFSE-labeled cells; and/or (ii) induces the secretion of cytokines, such as IL-6, IL-12, or IL-15, as measured in vitro with a dendritic cell activation assay. As used herein, the term “Langerin” has its general meaning in the art and refers to human C- type lectin domain family 4 member K polypeptide. In some embodiments, Langerin is the isoform of the human canonical sequence as reported by UniProtKB- Q9UJ71 (also referred as human CD207).
As used herein, the term "treatment" or "treat" refer to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patient at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse. The treatment may be administered to a patient having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a patient beyond that expected in the absence of such treatment. By "therapeutic regimen" is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy. A therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease. The general goal of an induction regimen is to provide a high level of drug to a patient during the initial period of a treatment regimen. An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular interval, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., pain, disease manifestation, etc.]). As used herein, the term “pharmaceutical composition” refers to a composition described herein, or pharmaceutically acceptable salts thereof, with other agents such as carriers and/or excipients. The pharmaceutical compositions as provided herewith typically include a pharmaceutically acceptable carrier. As used herein, the term “pharmaceutically acceptable carrier” includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic
agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical-Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. As used herein, the term “vaccination” or “vaccinating” means, but is not limited to, a process to elicit an immune response in a subject against a particular antigen. As used herein, the term "vaccine composition" is intended to mean a composition which can be administered to humans or to animals in order to induce an immune system response; this immune system response can result in the activation of certain cells, in particular APCs, T lymphocytes and B lymphocytes. As used herein the term "antigen" refers to a molecule capable of being specifically bound by an antibody or by a T cell receptor (TCR) if processed and presented by MHC molecules. An antigen is additionally capable of being recognized by the immune system and/or being capable of inducing a humoral immune response and/or cellular immune response leading to the activation of B- and/or T-lymphocytes. An antigen can have one or more epitopes or antigenic sites (B- and T- epitopes). As used herein, the term “adjuvant” refers to a compound that can induce and/or enhance the immune response against an antigen when administered to a subject or an animal. It is also intended to mean a substance that acts generally to accelerate, prolong, or enhance the quality of specific immune responses to a specific antigen. In the context of the present invention, the term "adjuvant" means a compound, which enhances both innate immune response by affecting the transient reaction of the innate immune response and the more long-lived effects of the adaptive immune response by activation and maturation of the antigen-presenting cells (APCs) especially Dendritic cells (DCs). As used herein, the expression "therapeutically effective amount" is meant a sufficient amount of the active ingredient of the present invention to induce an immune response at a reasonable benefit/risk ratio applicable to the medical treatment.
Antibodies of the present invention: The first object of the present invention relates to an antibody that is directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to a polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 “(Niv(G)B ectodomain”). In some embodiments, the light chain of the antibody is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain). In some embodiments, the heavy chain of the antibody is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain). The heavy chain and/or the light chain of the antibody is conjugated or fused to the Niv(G)B ectodomain via its C-terminal. In some embodiments, the heavy chain and/or the light chain of the antibody is fused to the N-terminal of the Niv(G)B ectodomain. In some embodiments, the heavy chain and/or the light chain of the antibody is conjugated to the Niv(G)B ectodomain by using chemical coupling. Several methods are known in the art for the attachment or conjugation of an antibody to its conjugate moiety. Examples of linker types that have been used to conjugate a moiety to an antibody include, but are not limited to, hydrazones, thioethers, esters, disulfides and peptide-containing linkers, such as valine-citruline linker. A linker can be chosen that is, for example, susceptible to cleavage by low pH within the lysosomal compartment or susceptible to cleavage by proteases, such as proteases preferentially expressed in tumor tissue such as cathepsins (e.g., cathepsins B, C, D). Techniques for conjugating polypeptides and in particular, are well-known in the art (See, e.g., Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy,” in Monoclonal Antibodies And Cancer Therapy (Reisfeld et al. eds., Alan R. Liss, Inc., 1985); Hellstrom et al., “Antibodies For Drug Delivery,” in Controlled Drug Delivery (Robinson et al. eds., Marcel Deiker, Inc., 2nd ed. 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents
In Cancer Therapy: A Review,” in Monoclonal Antibodies '84: Biological And Clinical Applications (Pinchera et al. eds., 1985); “Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody In Cancer Therapy,” in Monoclonal Antibodies For Cancer Detection And Therapy (Baldwin et al. eds., Academic Press, 1985); and Thorpe et al., 1982, Immunol. Rev.62:119-58; see also, e.g., PCT publication WO 89/12624.) Typically, the peptide is covalently attached to lysine or cysteine residues on the antibody, through N- hydroxysuccinimide ester or maleimide functionality respectively. Methods of conjugation using engineered cysteines or incorporation of unnatural amino acids have been reported to improve the homogeneity of the conjugate (Axup, J.Y., Bajjuri, K.M., Ritland, M., Hutchins, B.M., Kim, C.H., Kazane, S.A., Halder, R., Forsyth, J.S., Santidrian, A.F., Stafin, K., et al. (2012). Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA 109, 16101–16106.; Junutula, J.R., Flagella, K.M., Graham, R.A., Parsons, K.L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D.L., Li, G., et al. (2010). Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res.16, 4769– 4778). Junutula et al. (Nat Biotechnol.2008; 26:925-32) developed cysteine-based site-specific conjugation called ‘‘THIOMABs’’ (TDCs) that are claimed to display an improved therapeutic index as compared to conventional conjugation methods. Conjugation to unnatural amino acids that have been incorporated into the antibody is also being explored for ADCs; however, the generality of this approach is yet to be established (Axup et al., 2012). In particular the one skilled in the art can also envisage Fc-containing polypeptide engineered with an acyl donor glutamine-containing tag (e.g., Gin-containing peptide tags or Q- tags) or an endogenous glutamine that are made reactive by polypeptide engineering (e.g., via amino acid deletion, insertion, substitution, or mutation on the polypeptide). Then a transglutaminase can covalently crosslink with an amine donor agent (e.g., a small molecule comprising or attached to a reactive amine) to form a stable and homogenous population of an engineered Fc-containing polypeptide conjugate with the amine donor agent being site-specifically conjugated to the Fc- containing polypeptide through the acyl donor glutamine-containing tag or the accessible/exposed/reactive endogenous glutamine (WO 2012059882). In some embodiments, the heavy chain and/or the light chain of the antibody is conjugated to the Niv(G)B ectodomain by a dockerin domain or multiple domains to permit non-covalent coupling to cohesin fusion proteins as described in US20160031988A1 and US20120039916A1.
In some embodiments, the heavy chain and/or light of the antibody is fused to the Niv(G)B ectodomain to form a fusion protein. In some embodiments, the Niv(G)B ectodomain is fused either directly or via a linker to the heavy and/or light chain. As used herein, the term "directly" means that the first amino acid at the N-terminal end of the Niv(G)B ectodomain is fused to the last amino acid at the C-terminal end of the heavy or light chain. This direct fusion can occur naturally as described in (Vigneron et al., Science 2004, PMID 15001714), (Warren et al., Science 2006, PMID 16960008), (Berkers et al., J. Immunol.2015a, PMID 26401000), (Berkers et al., J. Immunol.2015b, PMID 26401003), (Delong et al., Science 2016, PMID 26912858) (Liepe et al., Science 2016, PMID 27846572), (Babon et al., Nat. Med.2016, PMID 27798614). In some embodiments, the N-terminal of the Niv(G)B ectodomain is fused to the C-terminal of the heavy chain directly or via a linker. In some embodiments, the linker is selected from the group consisting of SEQ ID NO:5 (FlexV1), SEQ ID NO:6 (f1), SEQ ID NO:7 (f2), SEQ ID NO:8 (f3), or SEQ ID NO:9 (f4), as described below. QTPTNTISVTPTNNSTPTNNSNPKPNP (flexV1, SEQ ID NO:5) SSVSPTTSVHPTPTSVPPTPTKSSP (f1, SEQ ID NO:6) PTSTPADSSTITPTATPTATPTIKG (f2, SEQ ID NO:7) TVTPTATATPSAIVTTITPTATTKP (f3, SEQ ID NO:8) TNGSITVAATAPTVTPTVNATPSAA (f4, SEQ ID NO:9) In some embodiments, the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope- rich peptide Niv(F)B”).
In some embodiments, the C-terminal of the light chain of the antibody is conjugated or fused to the N-terminal of the the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F)B”), and the C- terminal of the heavy chain of the antibody is conjugated or fused to the N-terminal of the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain). In some embodiments, the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope- rich peptide Niv(N)B”). In some embodiments, the C-terminal of the light chain of the antibody is conjugated or fused to the N-terminal of the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N)B”) and the C- terminal of the heavy chain of the antibody is conjugated or fused to the N-terminal of the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain). In some embodiments, the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and
- a light chain is conjugated or fused to both i) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F)B”) and ii) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope- rich peptide Niv(N)B”). In some embodiments, the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to both a fusion protein wherein i) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N)B”) is fused to ii) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F)B”). In some embodiments, the light chain is conjugated or fused to a fusion protein comprising the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F)B”) fused via its C-terminal directly or via a linker to the N-terminal of the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N)B”). In some embodiments, the light chain of the antibody is conjugated or fused to the fusion protein via its C-terminal. In some embodiments, the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N)B”) is fused via
a linker to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F)B”). In some embodiments, the linker consists of the amino acid sequence as set forth in SEQ ID NO:10. SEQ ID NO: 10 AEAAAKEAAAKA In some embodiments, the antibody of the present invention comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to both the fusion protein having at least 80% of identity with amino acid sequence as set forth in SEQ ID NO:11. SEQ ID NO:11 KYKIKSNPLTKDIVIKMIPNVSNMSQCTGSVMENYKTRLNGILTPIAEAAAKEAAAKAIQTKFAPGGYPLLW SFAMGVATTIDRSMGALNINRGYL In some embodiments, the antibody is an IgG antibody, preferably of an IgG1 or IgG4 antibody, or even more preferably of an IgG4 antibody. In some embodiments, the antibody is a chimeric antibody, in particular a chimeric mouse/human antibody. In some embodiments, the antibody is humanized antibody. Chimeric or humanized antibodies can be prepared based on the sequence of a murine monoclonal antibody prepared as described above. DNA encoding the heavy and light chain immunoglobulins can be obtained from the murine hybridoma of interest and engineered to contain non-murine (e.g., human) immunoglobulin sequences using standard molecular biology techniques. For example, to create a chimeric antibody, the murine variable regions can be linked to human constant regions using methods known in the art (see e.g., U.S. Patent No. 4,816,567 to Cabilly et al.). To create a humanized antibody, the murine CDR regions can be
inserted into a human framework using methods known in the art. See e.g., U.S. Patent No. 5,225,539 to Winter, and U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to Queen et al. In some embodiments, the antibody is a human antibody. In some embodiments, human antibodies can be identified using transgenic or transchromosomic mice carrying parts of the human immune system rather than the mouse system. These transgenic and transchromosomic mice include mice referred to herein as HuMAb mice and KM mice, respectively, and are collectively referred to herein as "human Ig mice." The HuMAb mouse® (Medarex, Inc.) contains human immunoglobulin gene miniloci that encode un-rearranged human heavy (µ and γ) and ĸ light chain immunoglobulin sequences, together with targeted mutations that inactivate the endogenous µ and ĸ chain loci (see e.g., Lonberg, et al., 1994 Nature 368(6474): 856-859). In another embodiment, human antibodies can be raised using a mouse that carries human immunoglobulin sequences on transgenes and transchomosomes such as a mouse that carries a human heavy chain transgene and a human light chain transchromosome. Such mice, referred to herein as "KM mice", are described in detail in PCT Publication WO 02/43478 to Ishida et al. In some embodiments, the antibody is specific for a cell surface marker of a professional APC. The antibody may be specific for a cell surface marker of another professional APC, such as a B cell or a macrophage. In some embodiments, the antibody is selected from an antibody that specifically binds to DC immunoreceptor (DCIR), MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CDl lb, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN-γ receptor and IL-2 receptor, ICAM-1, Fey receptor, LOX-1, and ASPGR. In some embodiments, the antibody is specific for CD40. In some embodiments, the anti-CD40 antibody derives from the 12E12 antibody and comprises: - a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GFTFSDYYMY (SEQ ID
NO:12), the CDR2H having the amino acid sequence YINSGGGSTYYPDTVKG (SEQ ID NO:13), and the CDR3H having the amino acid sequence RGLPFHAMDY (SEQ ID NO:14), - and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence SASQGISNYLN (SEQ ID NO:15) the CDR2L having the amino acid sequence YTSILHS (SEQ ID NO:16) and the CDR3L having the amino acid sequence QQFNKLPPT (SEQ ID NO:17). In some embodiments, the anti-CD40 antibody derives from the 11B6 antibody and comprises: - a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GYSFTGYYMH (SEQ ID NO:18), the CDR2H having the amino acid sequence RINPYNGATSYNQNFKD (SEQ ID NO:19), and the CDR3H having the amino acid sequence EDYVY (SEQ ID NO:20), and - a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence RSSQSLVHSNGNTYLH (SEQ ID NO:21) the CDR2L having the amino acid sequence KVSNRFS (SEQ ID NO:22) and the CDR3L having the amino acid sequence SQSTHVPWT (SEQ ID NO:23). In some embodiments, the anti-CD40 antibody derives from the 12B4 antibody and comprises: - a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GYTFTDYVLH (SEQ ID NO:24), the CDR2H having the amino acid sequence YINPYNDGTKYNEKFKG (SEQ ID NO:25), and the CDR3H having the amino acid sequence GYPAYSGYAMDY (SEQ ID NO:26), and - a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence RASQDISNYLN (SEQ ID NO:27) the CDR2L having the amino acid sequence YTSRLHS (SEQ ID NO:28) and the CDR3L having the amino acid sequence HHGNTLPWT (SEQ ID NO:29). In some embodiments, the anti-CD40 antibody is selected from the group consisting of selected mAb1, mAb2, mAb3, mAb4, mAb5 and mAb6 as described in Table A.
mAb1 [11B6 SEQ ID NO:30 SEQ ID NO:31
SEQ ID NO:30 (Amino acid sequence of variable heavy chain region (VH) (v2) of Humanized 11B6) EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINPYNGATSYNQNFKDRAT LTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGTTVTVSSAS SEQ ID NO:31 (Amino acid sequence of variable light chain (VL) Vk (v2) of humanized 11B6 VL) DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKVSNRFSGVPDRFSG SGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTK SEQ ID NO:32 (Amino acid sequence of variable heavy chain region VH (v3) of humanized 11B6) EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGLEWIGRINPYNGATSYNQNFKDRVT LTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGTTVTVSSAS SEQ ID NO:33 (VH amino acid sequence of mAb3 (12B4)) EVQLQQSGPELVKPGASVKMSCKASGYTFTDYVLHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKGKAT LTSDKSSSTAYMELSSLTSEDSAVYYCARGYPAYSGYAMDYWGQGTSVTVSSAS SEQ ID NO:34 (VL amino acid sequence of mAb3 (12B4)) DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGT DYSLTISNLEQEDIATYFCHHGNTLPWTFGGGTK SEQ ID NO:35 (VH amino acid sequence of mAb4 (24A3 HC)) DVQLQESGPDLVKPSQSLSLTCTVTGYSITSDYSWHWIRQFPGNKLEWMGYIYYSGSTNYNPSLKSRIS ITRDTSKNQFFLQLNSVTTEDSATYFCARFYYGYSFFDYWGQGTTLTVSSAS SEQ ID NO:36 (VL amino acid sequence of mAb4 (24A3 KC)) QIVLTQSPAFMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTS YSLTISSMEAEDAATYYCQQWSSNPLTFGAGTK SEQ ID NO:37 (VH amino acid sequence of mAb5) QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVT MTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSSAS
SEQ ID NO:38 (VL amino acid sequence of mAb5) DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGT DFTLTISSLQPEDFATYYCQQANIFPLTFGGGTK SEQ ID NO:39 (VH amino acid sequence of mAb6 (12E12 H3 Humanized HC)) EVQLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWVAYINSGGGSTYYPDTVKGRFT ISRDNAKNTLYLQMNSLRAEDTAVYYCARRGLPFHAMDYWGQGTLVTVSSAS SEQ ID NO:40 (VL amino acid sequence of mAb6 (Humanized K212E12)) DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAVKLLIYYTSILHSGVPSRFSGSGSGT DYTLTISSLQPEDFATYYCQQFNKLPPTFGGGTK In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:30, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:31. In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:32, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:31. In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:33, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:34. In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:35, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:36. In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:37, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:38. In some embodiments, the anti-CD40 antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:39, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:40. In some embodiments, the anti-CD40 antibody is a CD40 agonist antibody. CD40 agonist antibodies are described in WO2010/009346, WO2010/104747 and WO2010/104749. Other anti-CD40 agonist antibodies in development include CP-870,893 that is a fully human IgG2 CD40 agonist antibody developed by Pfizer. It binds CD40 with a KD of 3.48×10−10 M, but does not block binding of CD40L (see e.g., U.S. Pat. No. 7,338,660) and SGN-40 that is a humanized IgG1 antibody developed by Seattle Genetics from mouse antibody clone S2C6, which was generated using a human bladder carcinoma cell line as the immunogen. It binds to
CD40 with a KD of 1.0×10−9 M and works through enhancing the interaction between CD40 and CD40L, thus exhibiting a partial agonist effect (Francisco J A, et al., Cancer Res, 60: 3225- 31, 2000). Even more particularly, the CD40 agonist antibody is selected from the group consisting of selected mAb1, mAb2, mAb3, mAb4, mAb5 and mAb6 as described in Table A. In some embodiments, the antibody is specific for Langerin. In some embodiments, the antibody derives from the antibody 15B10 having ATCC Accession No. PTA-9852. In some embodiments, the antibody derives from the antibody 2G3 having ATCC Accession No. PTA- 9853. In some embodiments, the antibody derives from the antibody 91E7, 37C1, or 4C7 as described in WO2011032161. In some embodiments, the anti-Langerin antibody comprises a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H of the 15B10 antibody and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L of the 15B10 antibody. In some embodiments, the anti-Langerin antibody comprises a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H of the 2G3 antibody and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L of the 2G3 antibody. In some embodiments, the anti-Langerin antibody comprises a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H of the 4C7 antibody and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L of the 4C7 antibody. In some embodiments, the antibody is selected from the group consisting of selected mAb7, mAb8 and mAb9, as described in Table B. mAb7 SEQ ID NO:41 SEQ ID NO:42
mAb9 SEQ ID NO:45 SEQ ID NO:46 SEQ I
o ac sequece o a a e eay cain region (VH) of 15B10) SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSS LTSEDSAVYFCA SEQ ID NO:42 (Amino acid sequence of variable light chain (VL) 15B10) ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTLKISRVEAED LGLYFCS SEQ ID NO:43 (Amino acid sequence of variable heavy chain region (VH) of 2G3) SSVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLS SLTSEDSAVYFCA SEQ ID NO:44 (Amino acid sequence of variable light chain (VL) 2G3) VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALTITGAQTEDEA IYFCA SEQ ID NO:45 (Amino acid sequence of the heavy chain of 4C7) QVQLQQSGAELVRPGASVTLSCKASGYTFIDHDMHWVQQTPVYGLEWIGAIDPETGDTGYNQKFKGKAI LTADKSSRTAYMELRSLTSEDSAVYYCTIPFYYSNYSPFAYWGQGALVTVSAAKTTAPSVYPLAPVCGG TTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPALLQSGLYTLSSSVTVTSNTWPSQTITCNVAH PASSTKVDKKIEPRVPITQNPCPPLKECPPCADLLGGPSVFIFPPKIKDVLMISLSPMVTCVVVDVSED DPDAQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNRALPSPIEKTISK PRGPVRAPQVYVLPPPAEEMTKKEFSLTCMITGFLPAEIAVDWTSNGRTEQNYKNTATVLDSDGSYFMY SKLRVQKSTWERGSLFACSVVHEGLHNHLTTKTISRSLGKAS SEQ ID NO:46 (Amino acid sequence of light chain of 4C7) QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQRKPGSSPKPWIYATSNLASGVPARFSGSGSGTS YSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNF YPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKS FNRNEC In some embodiments, the anti-Langerin antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:41, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:42. In some embodiments, the anti-Langerin antibody comprises: a heavy chain wherein the variable domain has the the amino acid sequence set forth as SEQ ID NO:43, and a light chain wherein the variable domain has a sequence set forth as SEQ ID NO:44. In some embodiments, the anti-Langerin antibody comprises: a heavy chain having the the amino acid sequence set forth as SEQ ID NO:45, and a light chain having a sequence set forth as SEQ ID NO:46. The antibodies of the invention may be produced by any technique known per se in the art, such as, without limitation, any chemical, biological, genetic or enzymatic technique, either alone or
in combination. Knowing the amino acid sequence of the desired sequence, one skilled in the art can readily produce said polypeptides, by standard techniques for production of polypeptides. For instance, the antibodies of the invention can be synthesized by recombinant DNA techniques as is now well-known in the art. For example, these fragments can be obtained as DNA expression products after incorporation of DNA sequences encoding the desired (poly) peptide into expression vectors and introduction of such vectors into suitable eukaryotic or prokaryotic hosts that will express the desired polypeptide, from which they can be later isolated using well-known techniques. In some embodiments, the amino acid sequence herein described comprise one or more sequences originating from the restriction cloning site(s) present in the polynucleotide encoding for said amino acid sequence. Typically, said sequences may consist of 2 amino acid residues and typically include AP, AS, AR, PR, SA, TR, and TS sequences. In some embodiments, the amino acid sequences herein described the sequence of a signal peptide. As used herein, the term "signal peptide" has its general meaning in the art and refers to a pre-peptide which is present as an N-terminal peptide on a precursor form of a protein. The function of the signal peptide is to facilitate translocation of the expressed polypeptide to which it is attached into the endoplasmic reticulum. The signal peptide is normally cleaved off in the course of this process. The signal peptide may be heterologous or homologous to the organism used to produce the polypeptide. In some embodiments, the antibody of the present invention comprises: - a heavy chain having at least 80% of identity with the amino acid sequence as set forth in SEQ ID NO:47, and - a light chain having at least 80% of identity with amino acid sequence as set forth in SEQ ID NO:48. SEQ ID NO: 47 MGWSLILLFLVAVATRVHSEVQLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWVAY INSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGLPFHAMDYWGQGTLVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG LPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASQTPTNTISVTPTNNST PTNNSNPKPNPASQNYTRSTDNQAMIKDALQSIQQQIKGLADKIGTEIGPKVSLIDTSSTITIPANIGL LGSKISQSTASINENVNEKCKFTLPPLKIHECNISCPNPLPFREYKPQTEGVSNLVGLPNNICLQKTSN
QILKPKLISYTLPVVGQSGTCITDPLLAMDEGYFAYSHLEKIGSCSRGVSKQRIIGVGEVLDRGDEVPS LFMTNVWTPSNPNTVYHCSAVYNNEFYYVLCAVSVVGDPILNSTYWSGSLMMTRLAVKPKNNGESYNQH QFALRNIEKGKYDKVMPYGPSGIKQGDTLYFPAVGFLVRTEFKYNDSNCPIAECQYSKPENCRLSMGIR PNSHYILRSGLLKYNLSDEENSKIVFIEISDQRLSIGSPSKIYDSLGQPVFYQASFSWDTMIKFGDVQT VNPLVVNWRDNTVISRPGQSQCPRFNKCPEVCWEGVYNDAFLIDRINWISAGVFLDSNQTAENPVFTVF KDNEVLYRAQLASEDTNAQKTITNCFLLKNKIWCISLVEIYDTGDNVIRPKLFAVKIPEQCTLK SEQ ID NO:48 DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAVKLLIYYTSILHSGVPSRFSGSGSGT DYTLTISSLQPEDFATYYCQQFNKLPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK SFNRGEC In some embodiments, the antibody of the present invention comprises: - a heavy chain having at least 80% of identity with the amino acid sequence as set forth in SEQ ID NO:47, and - a light chain having at least 80% of identity with amino acid sequence as set forth in SEQ ID NO:49. SEQ ID NO: 49 DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAVKLLIYYTSILHSGVPSRFSGSGSGT DYTLTISSLQPEDFATYYCQQFNKLPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK SFNRGECASKYKIKSNPLTKDIVIKMIPNVSNMSQCTGSVMENYKTRLNGILTPIAEAAAKEAAAKAIQ TKFAPGGYPLLWSFAMGVATTIDRSMGALNINRGYL Polynucleotides, vectors and host cells of the present invention: A further object of the invention relates to a polynucleotide that encodes for a heavy chain and/or light chain of the antibody of the present invention. Typically, said polynucleotide is a DNA or RNA molecule, which may be included in any suitable vector, such as a plasmid, cosmid, episome, artificial chromosome, phage or a viral vector. So, a further object of the invention relates to a vector comprising a polynucleotide of the present invention. Such vectors may comprise regulatory elements, such as a promoter, enhancer, terminator and the like, to cause or direct expression of said antibody upon administration to a subject. Examples of promoters and enhancers used in the expression vector for animal cell include early promoter and enhancer of SV40, LTR promoter and enhancer of Moloney mouse leukemia virus, promoter and enhancer of immunoglobulin H chain and the like. Any
expression vector for animal cell can be used, so long as a gene encoding the human antibody C region can be inserted and expressed. Examples of suitable vectors include pAGE107, pAGE103, pHSG274, pKCR, pSG1 beta d2-4 and the like. Other examples of plasmids include replicating plasmids comprising an origin of replication, or integrative plasmids, such as for instance pUC, pcDNA, pBR, and the like. Other examples of viral vector include adenoviral, retroviral, herpes virus and AAV vectors. Such recombinant viruses may be produced by techniques known in the art, such as by transfecting packaging cells or by transient transfection with helper plasmids or viruses. Typical examples of virus packaging cells include PA317 cells, PsiCRIP cells, GPenv+ cells, 293 cells, etc. Detailed protocols for producing such replication- defective recombinant viruses may be found for instance in WO 95/14785, WO 96/22378, US 5,882,877, US 6,013,516, US 4,861,719, US 5,278,056 and WO 94/19478. A further object of the present invention relates to a host cell which has been transfected, infected or transformed by a polynucleotide and/or a vector according to the invention. The polynucleotides of the invention may be used to produce an antibody of the present invention in a suitable expression system. Common expression systems include E. coli host cells and plasmid vectors, insect host cells and Baculovirus vectors, and mammalian host cells and vectors. Other examples of host cells include, without limitation, prokaryotic cells (such as bacteria) and eukaryotic cells (such as yeast cells, mammalian cells, insect cells, plant cells, etc.). Specific examples include E.coli, Kluyveromyces or Saccharomyces yeasts. Mammalian host cells include Chinese Hamster Ovary (CHO cells) including dhfr- CHO cells (described in Urlaub and Chasin, 1980) used with a DHFR selectable marker, CHOK1 dhfr+ cell lines, NSO myeloma cells, COS cells and SP2 cells, for example GS CHO cell lines together with GS XceedTM gene expression system (Lonza), or HEK cells. The present invention also relates to a method of producing a recombinant host cell expressing the antibody according to the invention, said method comprising the steps of: (i) introducing in vitro or ex vivo a recombinant polynucleotide or a vector as described above into a competent host cell, (ii) culturing in vitro or ex vivo the recombinant host cell obtained and (iii), optionally, selecting the cells which express and/or secrete said antibody. Such recombinant host cells can be used for the production of antibodies of the present invention.
The host cell as disclosed herein are thus particularly suitable for producing the antibody of the present invention. Indeed, when recombinant expression are introduced into mammalian host cells, the polypeptides are produced by culturing the host cells for a period of time sufficient for expression of the antibody in the host cells and, optionally, secretion of the antibody into the culture medium in which the host cells are grown. The antibodies can be recovered and purified for example from the culture medium after their secretion using standard protein purification methods. Pharmaceutical and vaccine compositions: The antibodies as described herein may be administered as part of one or more pharmaceutical compositions. Except insofar as any conventional carrier medium is incompatible with the antibodies of the present invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. The antibodies as described herein are particularly suitable for preparing vaccine composition. Thus a further object of the present invention relates to a vaccine composition comprising an antibody of the present invention. In some embodiments, the vaccine composition of the present invention comprises an adjuvant. In some embodiments, the adjuvant is alum. In some embodiments, the adjuvant is Incomplete
Freund’s adjuvant (IFA) or other oil based adjuvant that is present between 30-70%, preferably between 40-60%, more preferably between 45-55% proportion weight by weight (w/w). In some embodiments, the adjuvant is Polyinosinic-polycytidylic acid (poly (I:C)) or Polyinosinic- Polycytidylic acid – poly-L-lysine carboxymethylcellulose (Poly-ICLC). In some embodiments, the vaccine composition of the present invention comprises at least one Toll- Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists. Therapeutic methods: The antibodies as well as the pharmaceutical or vaccine compositions as herein described are particularly suitable for inducing an immune response against Nipah virus and thus can be used for vaccine purposes. Therefore, a further object of the present invention relates to a method for vaccinating a subject in need thereof against Nipah virus comprising administering a therapeutically effective amount of the antibody of the present invention. In some embodiments, the antibodies as well as the pharmaceutical or vaccine compositions as herein described are particularly suitable for the treatment of Nipah virus infection. In some embodiments, the subject can be human or any other animal (e.g., birds and mammals) susceptible to Nipah virus infection (e.g., domestic animals such as cats and dogs; livestock and farm animals such as horses, cows, pigs, chickens, etc.). Typically said subject is a mammal including a non-primate (e.g., a camel, donkey, zebra, cow, pig, horse, goat, sheep, cat, dog, rat, and mouse) and a primate (e.g., a monkey, chimpanzee, and a human). In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a farm animal or pet. In some embodiments, the subject is a human. In some embodiments, the subject is a human infant. In some embodiments, the subject is a human child. In some embodiments, the subject is a human adult. In some embodiments, the subject is an elderly human. In some embodiments, the subject is a premature human infant. In some embodiments, the subject can be symptomatic or asymptomatic.
Typically, the active ingredient of the present invention (i.e., the antibodies and the pharmaceutical or vaccine compositions as herein described) is administered to the subject at a therapeutically effective amount. It will be understood that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. However, the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day. In particular, the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, in particular from 1 mg to about 100 mg of the active ingredient. An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day. The antibodies and the pharmaceutical or vaccine compositions as herein described may be administered to the subject by any route of administration and in particular by oral, nasal, rectal, topical, buccal (e.g., sub-lingual), parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active agent which is being used. The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
FIGURES: Figure 1. Epitope mapping of NiV G antigen associated to the CD40 mAb. Within the genome of NiV, ORF encoding the G, F and N proteins are highlighted in blue, orange and red respectively. Full-length aa sequences were screened for predicted HLA-I (NetMHC 4.0) and - II (NetMHCII 2.3) and linear B cell epitopes (BepiPred 2.0). For HLA-I and -II, colors intensity is representative of the density of predicted epitopes, with at least of coverage of 30% of the worldwide HLA. (Top) Ectodomain of the G protein associated to Gen-1 and Gen-2 vaccines. Figure 2. Epitope mapping of NiV F and N antigens associated to the CD40 mAb. F and N downselected domains associated to Gen-2 vaccine are represented. Figure 3. Schematic representation of Generation 1 (Gen-1) and Generation 2 (Gen-2) vaccines. Figure 4 Gen-1, Gen-2 and IgG4 control vaccine SDS PAGE profiles in non-reduced (NR) versus reduced (R) conditions. Figure 5: The G antigen fused to Gen-1 vaccine was confirmed by Western-Blot, using sera from Niv(G)-immunized mice and testing the in-house produced G protein as positive control. Molecular weight (kDa) markers are shown in the left lane. Arrows indicate the heavy chain (HC) and light chain (LC) of the vaccine constructions at the expected size, respectively. Figure 6: Size exclusion chromatography (SEC) of Gen-1 and Gen-2 vaccines with standard proteins size markers. Recombinant mAb are indicated by arrows. Figure 7: Binding assay of CD40.NiV vaccines to mouse cells expressing the human CD40 receptor. Mouse splenocytes from hCD40My/Hu Tg mice were incubated with 10nM of CD40.Niv Gen-1 mAbs and subsequently labeled for T-, B and DC cell markers, respectively. Untreated and splenocytes treated with the non-targeting IgG4.Niv were used as negative controls. Figure 8: Binding assay of CD40.NiV vaccines to AGM PBMCs. Same method as Fig-7, using PBMCs from naïve AGM. Two in-house produced anti-CD40 mAbs that were not associated with the G protein (clone VH3 and 11B6) were used as positive controls. Binding of the vaccine was demonstrated on B cells which express CD40, and to a less extend to monocytes / macrophages population. Figure 9: Gen-1 and -2 CD40.NiV vaccines induced humoral immune responses in hCD40Hy/Mu transgenic mice. G-specific IgG titers was determined by ELISA at day 0, 21 and 28 post-immunization of mice immunized twice with 10ug of CD40.NiV (Gen-1), Gen-2, or molar equivalent of the Niv(G) protein alone, with (plain circles) and without Poly-ICLC (open
circles). Medians of AUC [Min-Max] are represented and compared to control animals (Poly- ICLC alone). Figure 10: Neutralization activity of mice sera after vaccination detected by Luminex-based pseudo-neutralization assay at day 0, 21 and 28 post-immunization. Statistical analysis are same as in Fig-9 Figure 11: in vitro neutralization assay was performed on NiV-B infected cells using serial- diluted sera collected at d28 post-immunization. IC50 was calculated and reported as titers. Statistical analysis are same as in Fig-9. Figure 12: Niv(G)-specific B cells in dLN were stained using biotinylated NiV(G) proteins. (left) Representative dot plots. Niv(G)-specific B cells are considered double positive for the two anti-Biotin mAbs. (right) Percentage (%) of GC B-cells (FAS+ GL-7+) and Percentage Niv(G)-specific B cells among this population. Animals were immunized with 30ug of CD40.NiV (Gen-2) with Poly-ICLC and were compared to the Poly-ICLC negative group. Mann-Whitney unpaired t-test, **, p<0.01; ***, p<0.0001. Figure 13: Gen-1 and -2 CD40.NiV vaccines induced cellular immune responses in hCD40Hy/Mu transgenic mice. IFN-g T cells responses to the G, F and N overlapping pools of peptides were assessed by ELISpot, one week post boost. (left) Specific IFN-g responses to the G antigen of mice immunized by Gen-1 and Gen-2, respectively. Number of spots are reported per million of splenocytes (right) Total specific IFN-g responses to the three antigens of Gen- 2, in mice immunized with 10 and 30ug of vaccine, respectively. (Bottom right) Percentages of G, F and N-specific responses, at 10 and 30ug of vaccine, respectively. Plain circle, with Poly-ICLC, open circles, without Poly-ICLC. Figure 14: Immune responses of AGM vaccinated with CD40.Niv Gen-2. Schematic representation of the study design. Diamonds are representative of sampling. Nine AGM were immunized with CD40.NiV(Gen-2) with Poly-ICLC with 3-week prime-boost interval. Niv(G)-specific IgG (left) and IgA (right) titers, in the Poly-ICLC animal group (n=3, left) vs the vaccinated animal group (n=9, right), at 0, 10, 21, 35 and 56 days post-prime, respectively. Individual Ig titers (log(1/EC50)) are represented, and whiskers indicate medians [Min-Max] for each group and time-point, respectively. Prime and boost are indicated by arrows. Dotted line, threshold of Ig titer detection. Figure 15: As in Figure 10, neutralization activity of AGM sera was measured by indirect inhibition assay Figure 16: In vitro neutralization of NiV-B by sera from vaccinated AGM.
Figure 17: As in Fig-13, total specific IFN- ^ responses to the G, F and N antigens were measured in AGM circulating PBMCs collected at day 21 and 35 post-immunization. Number of spots are reported per million of PBMC. Pointed line represents threshold for positivity defined by the mean responses (+3SD) of the non-vaccinated AGM group. (right) Percentage (%) of specific T cell response to each vaccine antigen (mean ± SD). Figure 18: In vitro NiV-B neutralization activity of AGM sera measured post immunization and post-challenge (day 80 pi): poly-ICLC group (n = 3, black circle); CD40.NiV (Gen-2) with poly-ICLC (n = 9, white circle); thin black line, modeling of the decrease in neutralizing Abs after the peak of the response (day 35). Figure 19: Protection assay in AGM. Survival curve. Nine AGM were immunized twice with CD40.NiV (Gen-2) and challenged with 102 Pfu NiV-B (intratracheal route). Height naïve animals were used as controls. Gehan-Breslow-Wilcoxon test, ****, p<0.0001. Figure 20: Clinical scores and temperatures of naïve (black circle) and vaccinated AGMs (white circle). Dotted line score threshold for ethical considerations (left panel); dotted line: median temperature at day 0 (right panel). Figure 21: Viral dissemination post-challenge. (A) (left) Amount of viral NiV RNA quantified by RT-PCR (N gene) in PBLs. Values were normalized against those of the GADPH housekeeping gene. Genomic RNA was measured by RT-qPCR in nasal (middle) and pharyngeal (right) swabs. Mean values (± SEM) are presented for the non-vaccinated (black circle , n = 7) versus CD40.NiV (Gen-2) vaccinated (white circle, n = 9) groups. (B) Same as in A for fluids collected at necropsy. EXAMPLE: Methods: Molecular cloning and production: Generation-1: The ectodomain of the NiV-B G protein (Figure 1, The Bangladesh strain (NiVB) (GenBank: AY988601.1) (Harcourt BH et al., Emerging Infect. Dis.2005) ectodomain highlighted) was cloned into the UCOE vector, at the C-terminal end of the Heavy-chain of the anti-CD40 mAb (clone 12E12/VH3) with a flexible linker (see Figure 3). Generation-2: AA sequence of the F and N proteins (strain Bangladesh) were screened for the density of predicted MHC-I and –II epitopes and the diversity of HLA using online software (NetMHC) (Figure. 2). Sequences were further breakdown by analyzing the presence of predicted linear B cell epitopes, and by screening non-hydrophobic stable protein domains. One
peptide in F and one in N were associated with linker domains to the C-terminal end of the anti- CD40 light chain (clone 12E12/VH3) (see Figure 3 right). Production in CHO cell line: CHO cells were transfected by the plasmids expressing H- and L-chains (see Figure 3). Culture supernatant were collected, protein A captured and purified on FPLC. Purified vaccine batches were controlled for their endotoxin levels (<0.5 ng/mg of protein). Biochemical Quality controls: Quality of vaccine batches was analyzed by 1) SDS-PAGE analysis (under reduced and non- reduced conditions) followed by a Coomassie Blue staining (Figure 4), and ii) a SEC analysis using standard proteins (Figure 6). Gen1 vaccine was assessed by western blot (Figure 5), using sera from C57BL/6 mice immunized by the in-house produced G protein (+CpG). The H-chain fused with the G protein was revealed by the mouse sera. Binding assay: Gen-1 antibodies and same 12E12/VH3 clone without any antigen were marked by a fluorochrome. The clone 11B6 was also tested in parallel as positive control. Mouse splenocytes from hCD40 Tg mice (Figure 7) and PBMCs from AGM (Figure 8) were incubated with fluorescent vaccine in vitro. Cells were phenotyped and analyzed by FACS. Immunological responses in hCD40 Tg mice: hCD40Hy/Mu Tg mice (CO-1704 hTnfrsf5-OST5(CD40) Knock-in HOM) were immunized subcutaneously twice with either CD40.NiV(G) (Gen-1 or -2) or the Niv(G) protein alone with or without any adjuvant (see Table 1). Sera were collected and week 0, 3 and 4. Splenocytes were collected at week 4. Sera were tested by ELISA for their amount of G-specific IgG. Serial dilution were assessed to determine antibody titers (Figure-9). Neutralizing activity of serum Ab was measured by in house Luminex assay (Figure 10) or in vitro NiV-B neutralization assay (Figure 11). Serial dilution were performed to determine neutralization effect of the sera on NIV infection. Formation of Germinal center B cells and G-specific B cells within this population was estimated by FACS (Figure-12). Splenocytes were stimulated in vitro with either a pool of overlapping peptides (OVLP at 1 ug/mL; Figure 13) encompassing the downselected domains from the NiV G, F and N proteins contained within the vaccine (Figures 1 and 2). IFN-g production was assessed by ELISpot. Immunological responses in AGM: Nine AGM were vaccinated twice with CD40.NiV(Gen-2) vaccine with 3-week intervals. Three naïve animals were used as controls. Blood draws were regularly collected to measure by ELISA G-specific IgG and IgA (Figure-14) in sera. Neutralizing activity of sera was
determined as in mouse studies (Figures 15, 16, and 18). IFNg-ELISPOT was performed on PBMCs collected at day 21 and 35 post-immunization (Figure 17). Challenge assay: Vaccinated animals (n=9) versus naïve AGM (n=8) were challenged intratracheally with 102pfu of Niv-B. Survival was observed over three weeks (Figure 19). Clinical and hematobiochemical follow-up: Clinical exams were performed everyday post-challenge and the following parameters were scored: temperature, weight, dehydration, breath, reactivity, feces exams and neurological symptoms. Animals were euthanized when the total score reached > 15 for ethical reasons (Figure 20). Virology RNA extraction from infected AGM PBL: Blood samples from infected AGMs collected in EDTA tubes were diluted in Pharmalyse buffer, vortexed, and incubated in the dark for 15 min. They were then centrifuged at 200 x g for 5 min and the pellets washed in 2 mL PBS 1% FBS, 2 mM EDTA. Finally, pellets were resuspended in 600 μL RLT lysis buffer and purified following the manufacturer’s instructions (Macherey Nagel). Samples were stored at -80°C till use. RT-qPCR: Viral RNA was extracted using a Qiamp Viral RNA Kit (Qiagen) for serum, swabs, urine, BAL, vitreous humor, and thoracic exudate samples and a Nucleospin Kit (Macherey Nagel) for PBMCs and organs. Viral load was evaluated by one-step RT-qPCR using NiV-N-specific primers and GAPDH primers, if necessary (Figure 21). Results: In silico down-selection of NiV predictive immunogenic peptides and CD40.NiV vaccine design Two CD40.NiV vaccine candidates have been successfully produced. While Gen-1 and -2 contains the gold-standard Niv G (glycoprotein) surface antigen, Gen-2 vaccine is also associated with in silico down selected peptides from the F and N proteins, and that are predicted to be enriched in T- and B-cells epitopes (Figures 1 to 8). The NiV surface glycoprotein (G) is a gold-standard antigen for inducing protective humoral responses. Other cellular effectors, such as helper and effector T-cells, may also participate in host defense. We screened the NiV G ectodomain (ECD) to identify vaccine epitopes using NetMHC 4.0 and NetMHCII 2.3 software, which predict T-cell epitopes that bind to a large panel of class-I and
-II HLA molecules, respectively. Linear B-cell epitopes were predicted using BepiPred 2.0. The NiV G ECD vaccine region was predicted to contain 3522 and 15 T- and B-cell epitopes, respectively. Due to their conservation between NiV strains, we further identified vaccine epitopes from the fusion (F) and nucleocapsid (N) proteins. Regions with strong binder epitopes and the highest HLA coverage were highlighted, as well as linear B-cell epitopes. The NiV F (aa 45-90) and NiV N (aa 318-355) down-selected peptides contain 356 and 266 predicted T- cell epitopes and three and linear B-cell epitopes, respectively. Globally, these amino acid sequences were screened for homology with other Henipaviruses, obtaining 100% homology between different Nipah strains for the F and N peptides and more than 98% for NiV G ECD. (Figure 1 to 8) We next engineered vectors expressing NiV-B G ECD fused to the C-termini of the Heavy Chains (HCs) of the anti-human CD40 humanized 12E12 IgG4 monoclonal antibody, with additional selected peptides of NiV F and NiV N fused to the C-termini of the Light chains (LC) (named CD40.NiV) (Figure 3). Vaccines were produced in CHO cells and controlled for their quality. We confirm, here, binding of the CD40.NiV vaccine to the human CD40 and AGM CD40 receptor in vitro using splenocytes from mice transgenic for the human CD40 receptor (CD40Hy/Mu transgenic mice; hCD40Tg) and PBMCs from AGM, respectively (Figure 7-8) CD40.NiV induces specific T- and B-cell responses in hCD40Tg mice We first evaluated the immunogenicity in hCD40My/Hu Tg mice. hCD40Tg mice were immunized with two subcutaneous (SC) injections of CD40.NiV (Gen-1 or Gen-2) vaccine (10 μg) or an equivalent amount of NiV G protein, both with poly-ICLC (50 μg) on days 0 and 21. Antibody-mediated immune responses were first evaluated by Luminex assay. Our results showed a significant G-specific IgG titer with both vaccines (Figure 9). Three weeks post- prime, mice immunized with the CD40-targeted NiV G protein showed significantly higher anti-NiV G IgG levels (P < 0.01), highlighting the benefit conferred by the DC-targeting system. This antibody level was markedly improved i) when the G protein was targeted to APCs, and ii) when mice were immunized with adjuvant. We next compared the avidity of NiV G-specific IgG post-boost using a multiplex immunoassay approach. Strikingly, the avidity index was significantly improved when NiV G was targeted to the CD40 receptor (P < 0.05), suggesting an advantage of such targeting for inducing B-cell affinity maturation (data not shown). Noteworthy, we set-up an in-house Luminex-based assay to assess the inhibition of the binding of G to the Ephrin B2 receptor by the IgG circulating in the sera. Our results revealed a strong capacity of immunized sera to pseudo-neutralize this protein G / receptor interaction
(Figure 10). Strikingly, the neutralization capacity of vaccine-induced IgG was confirmed by a neutralization assay performed at the BSL-4 (Figure 11). G-specific B cells were detected by FACS within the germinal center B cells populations of immunized mice (Figure 12). We further confirmed the induced B-cell responses in CD40.NiV (+ poly-ICLC) vaccinated mice by detecting germinal center (GC) B-cells within the draining lymph nodes (dLN) (P < 0.001 as compared to the Poly-ICLC control group) (Figure 12). Furthermore, FACS-staining showed a significant NiV G-specific GC B-cell population in the dLN of vaccinated animals (P < 0.01). To demonstrate the specific T-cell responses against the various antigens from CD40.NiV, we performed an IFN-g ELISpot assay on splenocytes using pools of overlapping peptides (Figure 13). We detected dose-dependent IFN-g producing cells specific for NiV G ECD, as well as NiV F and N peptides. Last, we demonstrated by IFN-g ELISpot performed on mouse splenocytes that Gen-2 vaccine induced cellular responses specific to the G, F and N peptides compromised within the vaccine, respectively (Figure 13). Overall, these results demonstrate the immunogenicity of the CD40.NiV vaccine candidate. The CD40.NiV vaccine induces early and robust humoral and T-cell responses in AGMs We then assessed cellular and humoral responses of the Gen-2 vaccine in the African Green Monkey (AGM) model, which is the most relevant model to test the infection by the Bangladesh NiV strain. Twelve animals have been imported and housed at the Bioprim animal center (Toulouse). Two groups of animals have been immunized in a prime-boost homologous regimen, as follow: 3 AGM with Poly-ICLC alone versus 9 AGM with 200ug of Gen-2 vaccine + Poly-ICLC. A serial collection of blood samples have been performed as follow: (i) sera for G-specific Ig titer and neutralization, and (ii) PBMCs for IFN-g ELISpot (Figure 14). We demonstrated that our vaccine candidate induced a strong and long-lasting humoral response, with circulating IgG neutralizing the virus in vitro (assessed in BSL-4) (Figures 14 to 16). All vaccinated animals showed specific and significant IgG and IgA titers 10 days post-prime (Figure 14). IgG titers increased over time and then remained the same until day 56, whereas serum IgA levels dropped. Vaccination elicited a neutralization potential of NiV G-specific IgG by day 10 post-prime, reaching significance two weeks post-boost (mean neutralization titer 3.2 (±0.2), P < 0.001), and remained high until day 56 (Figures 15, 16 and 18). We estimated a significant average decrease of 0.016 logs neutralization titer per day, leading to a prediction of the maintenance of a neutralization titer above the detectable threshold (mean log titer 2.2 (±0.1)) up to 100 days following the boost. The neutralizing capacity of specific antibodies was confirmed post-prime and post-boost using the Luminex-based
surrogate inhibition assay (P < 0.001) (data not shown). We assessed cross neutralization to NiV-B, -M (Malaysia) and -C (Cambodia), and HeV using the sera of five vaccinated AGMs by in vitro infection of VeroE6 cells with recombinant (F/G)VSV particles (data not shown). Two weeks post-boost, all animals exhibited comparable cross-reactive humoral responses to NiV (F/G) proteins, as well as positive cross-reactive responses to Hendra virus (data not shown). IFN-g ELISpot assays were conducted on PBMCs collected on day 21 (before the boost) and day 35 post-prime, using pools of peptides for each vaccine antigen (Figure 17). The overall responses were significant two weeks post-boost (P< 0.05) and positive in 5/8 tested animals. Our results highlighted a polyclonal IFN-g T cells responses to all vaccine antigens (Figure 17). Overall, CD40.NiV (Gen-2) induced cellular responses associated with strong, rapid and durable humoral responses in an AGM model, with high titers of neutralizing antibodies. Clinical Outcomes and survival for challenged animals Then we tested vaccine-induced protection against Niv infection in African green monkeys (AGM). Control and vaccinated AGM have been transferred to the BSL-4 where they have been challenged with Niv (102 pfu intratracheal, Bangladesh strain). The dose for the challenge was selected based on previous experiments that included five non-vaccinated animals infected under the same conditions. Strikingly, we observed a complete protection of vaccinated animals (at Day 22 post-challenge, n=8), whereas all non-vaccinated animals died between D7 and D11 (n=8) (Figure 19). From a clinical standpoint, only mild and transient clinical signs were evident in the vaccinated animals, with a mean clinical score remaining below 6, mostly attributed to a lack of reactivity (Figure 20). The control group showed a high grade clinical score, with apathy, tachypnea, dyspnea, and gastrointestinal symptoms, along with fever (above 38.9°C in all animals). The animals showed various hematological and serum biochemistry changes during the challenge phase (data not shown). Enzyme activity levels (aspartate aminotransferase, AST; creatine kinase, CK) reflecting hepatic disorders were above normal values during the critical disease period for controls but not the vaccinated animals. We also observed perturbations of the white and red blood counts in the controls, which exhibited lymphopenia and thrombocytopenia, whereas we observed no significant abnormalities in the vaccinees during the post-immunization and challenge phases. Necropsy studies revealed lesions and the pathophysiological process of the NiV-B infection in control animals (data not shown). Examination of the lung tissue showed interstitial pneumonia, edema, and vasculitis,
with inflammatory cell infiltrates for all controls but rarely for the vaccinated animals (observed in 2 of 9 animals, AGM #S1134 and #O1376, data not shown). Non-vaccinees showed follicular depletion in the spleen, whereas eight CD40.NiV-vaccinated AGMs showed follicular hyperplasia, suggesting that a strong adaptive immune response was induced post-challenge. Of note, we observed no relevant lesions in the frontal cortex of any animals. From a clinical point of view, CD40.NiV (Gen-2) appears to confer full protection against disease progression and death. Plasma and tissue viral loads in challenged AGMs We assessed NiV viremia by qRT-PCR in PBLs from vaccinated and control animals at regular time-points and at termination of the study (euthanasia or 28 dpc) for organs, fluids, and swabs. All controls (n = 3 receiving poly-ICLC plus n = 4 naïve AGM) exhibited a high level of NiV- B in PBLs (ranging from 4.5-5.5 log10 copies/mL) detectable from 7 to 8 dpc, whereas we detected no virus in vaccinated subjects until 22 dpc (Figure 21A). Except for one animal (AGM #S1134), for which NiV-B transcripts were detected by RT-PCR in the lung, NiV-B replication in nasal and nasopharyngeal swabs, fluids, including broncho-alveolar lavages (BALs), sera, urine, and thoracic exudates, and organs (lung, spleen, and neurological tissue) was undetectable in immunized AGMs, whereas it was detected at high levels in controls (Figure 21B). This strong antiviral effect was confirmed by the lack of expression of the NiV N protein in tissues of the lungs and spleen, as assessed by histo-immunofluorescence (data not shown). Viral syncytia were detected in the lungs of non-immunized animals. Of note, NiV-B infection of the brain could not be confirmed by histo-immunofluorescence. Overall, CD40.NiV (Gen-2) vaccination led to sterilizing immunity that limited viral propagation, as well as viral shedding, in AGMs. Immunological and cytokine features of challenged animals We further characterized the post-challenge immune responses by immunological phenotyping of the cell populations from 0 to 22 dpc. The succumbing animals showed profound and significant defects in the lymphoid populations (CD20+ B- and CD3+ T-cells) (data not shown). Among T cells, the percentage of CD8+ T-cells was markedly reduced during NiV infection (data not shown). These changes were transitional and not significant in the vaccinated group. Innate immunity was also affected by NiV-B infection, with the almost complete disappearance of circulating monocytes in succumbing animals, whereas the number of inflammatory, intermediate, and classical monocytes in the vaccinees remained stable after the critical period
of infection (7 to 9 dpc) (data not shown). Overall, these data indicate that exposure to NiV challenge induces dramatic perturbations of innate and adaptive cellular immunity, which are attenuated and/or nonsignificant in CD40.NiV-immunized animals. Changes in blood-cell gene expression in vaccinated AGM To decipher early changes in gene expression associated with the vaccination, we performed RNA sequencing analysis of peripheral whole blood at D0 (before prime) and one day post- prime (PP, D1), just before the boost (D21), and one day post-boost (PB, D22) in animals receiving adjuvanted CD40.NiV(Gen-2). Given the small number of animals in the adjuvant control group, we analyzed the differentially expressed genes (DEGs) at different time points relative to baseline in the vaccinated animals. Principal component analysis (PCA) showed changes in gene abundance PP and PB relative to baseline (D0 before injection) (data not shown). In total, 773 DEGs were significantly modulated at D22 (one day post-boost). Interestingly, among these DEGs, 437 were noted at D1 and D22 (one day PP and PB). An additional 236 DEGs were common between day 1 PP and PB (data not shown). The most highly upregulated genes from D0 to D22 included those that play a major role in antiviral innate and proinflammatory responses (e.g., ISG15, MX1, IFI44, CXCL10, and IL-27) and adaptive immunity (e.g., antigen uptake by SIGLEC-1, T-cell chemotaxis by CCL8, and CXCL11) (data not shown). Most of these transcripts were found to be upregulated PP and PB (data not shown). A panel of the most highly downregulated genes was also associated with a signature of a primary or secondary immune response to the vaccine (e.g., CD1c, CD79A, CCR6, and CXCR4). Globally, the most highly upregulated and downregulated genes in vaccinated animals were predominantly associated with pathways involved in immune system processes and the defense against viruses and other organisms (data not shown). The humoral immune response mediated by circulating immunoglobulin was specifically promoted PB (data not shown), highlighting a prominent antibody-mediated response after the second injection of CD40.NiV (Gen-2). Overall, the antiviral defense module of genes was the most significantly upregulated on D22 (data not show). The detailed kinetics of the genes involved in this module showed rapid and significant activation of all PP and PB (data not shown). Ten transcripts, including interferon- inducible antiviral proteins (RSAD2 and RIG1), were significantly upregulated PB relative to PP. Other gene network modules were also highlighted PP and PB (e.g., response to virus, cytokine signaling, neutrophil degranulation, and regulation of leukocyte activation). Although
we could not discriminate between effects of the vaccine and the adjuvant in the vaccinees, our transcriptomic analysis highlights a vaccine-induced gene signature. Conclusion: Here, we demonstrate the potency of an innovative DC-targeting vaccine candidate to prevent NiV-B infection in challenge experiments in an AGM model. More than three decades after discovering the immunological properties of DCs, we prove, for the first time, that targeting viral antigens to professional APCs can be efficiently used as a prophylactic means against a viral challenge at a lethal dose. The DC-targeting strategy allowed us to design a subunit construct containing immunogenic and cross-reactive epitopes from the F and N NiV proteins, in addition to the NiV G ECD, in contrast to most other NiV vaccine platforms (Bossart et al., 2012; Foster et al., 2022; Geisbert et al., 2021; 287 Loomis et al., 2020; Mohammed et al., 2020; Woolsey et al., 2023; Yoneda et al., 2013). The CD40.NiV vaccine induced both IgG and IgA antibodies as early as 10 days post-prime in AGMs. We also show that neutralizing responses can be maintained, with a stable estimated mean log titer of approximately 2.2 (±0.1) 100 days after the peak of the Ab response. Responses were showed to cross-neutralize multiple strains of NiV, but also HeV. Although detectable at a lower level, we found that the CD40.NiV vaccine elicited a T-cell response against the NiV G ECD and down-selected F and N peptides in two preclinical models. Transcriptomic analysis showed a common set of DEGs one day following prime and boost (D1 and D22), including those for antiviral innate (ISG15, MX1, IFI44) and adaptive immunity. The differentially expressed genes in vaccinated animals were predominantly associated with pathways involved in immune system processes and the defense against viruses involving innate immunity at earlier time point (D1, PP) as described with other vaccine strategies(Hagan et al., 2022). Interestingly, the modulation of gene pathways associated with humoral responses was significant post-boost at day 22. Overall, these results highlight a vaccine signature associated with the protective effect of the vaccine. REFERENCES: Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.
Claims
CLAIMS: 1. An antibody that is directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to a polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 “(Niv(G)B ectodomain”). 2. The antibody of claim 1 wherein the light chain of the antibody is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain). 3. The method of claim 1 wherein the heavy chain of the antibody is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain). 4. The antibody according to any one of claim 1 to 3 wherein the heavy chain and/or the light chain of the antibody is conjugated or fused to the Niv(G)B ectodomain via its C- terminal. 5. The antibody according to any one of claims 1 to 3 wherein the heavy chain and/or the light chain of the antibody is fused to the N-terminal of the Niv(G)B ectodomain. 6. The antibody according to any one of claims 1 to 5 wherein the heavy chain and/or light of the antibody is fused to the Niv(G)B ectodomain to form a fusion protein. 7. The antibody according to any one of claims 1 to 6 wherein the Niv(G)B ectodomain is fused either directly or via a linker to the heavy and/or light chain. 8. The method of claim 1 wherein the linker is selected from the group consisting of SEQ ID NO:5 (FlexV1), SEQ ID NO:6 (f1), SEQ ID NO:7 (f2), SEQ ID NO:8 (f3), or SEQ ID NO:9 (f4). 9. The antibody according to any one of claims 1 to 8 wherein the antibody comprises:
- a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope- rich peptide Niv(F)B”). 10. The antibody according to any one of claims 1 to 8 wherein the antibody comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope- rich peptide Niv(N)B”). 11. The antibody according to any one of claims 1 to 8 wherein the antibody comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to both i) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F)B”) and ii) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope- rich peptide Niv(N)B”). 12. The antibody according to any one of claims 1 to 8 wherein the antibody comprises:
- a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and, - a light chain is conjugated or fused to both a fusion protein wherein i) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N)B”) is fused to ii) the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope-rich peptide Niv(F)B”). 13. The antibody of claim 12 wherein the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (I) at position 318 to the amino acid residue (L) at position 355 in SEQ ID NO:3 (“predicted epitope-rich peptide Niv(N)B”) is fused via a linker to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (K) at position 45 to the amino acid residue (I) at position 90 in SEQ ID NO:2 (“predicted epitope- rich peptide Niv(F)B”). 14. The antibody of claim 13 wherein the linker consists of the amino acid sequence as set forth in SEQ ID NO:10. 15. The antibody of claim 14 wherein the antibody comprises: - a heavy chain of the antibody that is conjugated or fused to the polypeptide having at least 80% of identity with the amino acid sequence that ranges from the amino acid residue (Q) at position 71 to the amino acid residue (T) at position 602 in SEQ ID NO:1 (Niv(G)B ectodomain) and - a light chain is conjugated or fused to both the fusion protein having at least 80% of identity with amino acid sequence as set forth in SEQ ID NO:11. 16. The antibody according to any one claims 1 to 15 wherein the antibody an IgG4 antibody.
17. The antibody according to any one of claims 1 to 16 wherein he antibody is specific for CD40. 18. The antibody of claim 17 wherein: - the anti-CD40 antibody derives from the 12E12 antibody and comprises: o a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GFTFSDYYMY (SEQ ID NO:12), the CDR2H having the amino acid sequence YINSGGGSTYYPDTVKG (SEQ ID NO:13), and the CDR3H having the amino acid sequence RGLPFHAMDY (SEQ ID NO:14), o and a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence SASQGISNYLN (SEQ ID NO:15) the CDR2L having the amino acid sequence YTSILHS (SEQ ID NO:16) and the CDR3L having the amino acid sequence QQFNKLPPT (SEQ ID NO:17) - the anti-CD40 antibody derives from the 11B6 antibody and comprises: o a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GYSFTGYYMH (SEQ ID NO:18), the CDR2H having the amino acid sequence RINPYNGATSYNQNFKD (SEQ ID NO:19), and the CDR3H having the amino acid sequence EDYVY (SEQ ID NO:20), and o a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence RSSQSLVHSNGNTYLH (SEQ ID NO:21) the CDR2L having the amino acid sequence KVSNRFS (SEQ ID NO:22) and the CDR3L having the amino acid sequence SQSTHVPWT (SEQ ID NO:23) - the anti-CD40 antibody derives from the 12B4 antibody and comprises: o a heavy chain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, the CDR1H having the amino acid sequence GYTFTDYVLH (SEQ ID NO:24), the CDR2H having the amino acid
sequence YINPYNDGTKYNEKFKG (SEQ ID NO:25), and the CDR3H having the amino acid sequence GYPAYSGYAMDY (SEQ ID NO:26), and o a light chain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, the CDR1L having the amino acid sequence RASQDISNYLN (SEQ ID NO:27) the CDR2L having the amino acid sequence YTSRLHS (SEQ ID NO:28) and the CDR3L having the amino acid sequence HHGNTLPWT (SEQ ID NO:29). 19. The antibody of claim 17 wherein the anti-CD40 antibody is selected from the group consisting of selected mAb1, mAb2, mAb3, mAb4, mAb5 and mAb6 as described in Table A. 20. The antibody of claim 1 that comprises: - a heavy chain having at least 80% of identity with the amino acid sequence as set forth in SEQ ID NO:47, and - a light chain having at least 80% of identity with amino acid sequence as set forth in SEQ ID NO:48. 21. The antibody of claim 1 that comprises: - a heavy chain having at least 80% of identity with the amino acid sequence as set forth in SEQ ID NO:47, and - a light chain having at least 80% of identity with amino acid sequence as set forth in SEQ ID NO:49. 22. A polynucleotide that encodes for a heavy chain and/or light chain of the antibody according to any one claims 1 to 21. 23. A vector comprising the polynucleotide of claim 22 24. A host cell which has been transfected, infected or transformed by the polynucleotide of claim 22 and/or the vector of claim 23. 25. A vaccine composition comprising the antibody according to any one claims 1 to 21.
26. A method for vaccinating a subject in need thereof against Nipah virus comprising administering a therapeutically effective amount of the antibody according to any one of claims 1 to 21.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22306485 | 2022-10-05 | ||
EP22306485.8 | 2022-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024074571A1 true WO2024074571A1 (en) | 2024-04-11 |
Family
ID=83691084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/077477 WO2024074571A1 (en) | 2022-10-05 | 2023-10-04 | Dc-targeting vaccine against nipah virus infection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024074571A1 (en) |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
WO1995014785A1 (en) | 1993-11-23 | 1995-06-01 | Rhone-Poulenc Rorer S.A. | Composition for the in vivo production of therapeutic products |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1996022378A1 (en) | 1995-01-20 | 1996-07-25 | Rhone-Poulenc Rorer S.A. | Cells for the production of recombinant adenoviruses |
US5882877A (en) | 1992-12-03 | 1999-03-16 | Genzyme Corporation | Adenoviral vectors for gene therapy containing deletions in the adenoviral genome |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO2002043478A2 (en) | 2000-11-30 | 2002-06-06 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7338660B2 (en) | 2001-11-09 | 2008-03-04 | Abgenix, Inc. | Methods of treating cancer and enhancing immune responses with antibodies that bind CD40 |
WO2010009346A2 (en) | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
WO2010104749A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
WO2011032161A2 (en) | 2009-09-14 | 2011-03-17 | Baylor Research Institute | Vaccines directed to langerhans cells |
US20120039916A1 (en) | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
WO2012059882A2 (en) | 2010-11-05 | 2012-05-10 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
US20160031988A1 (en) | 2007-02-02 | 2016-02-04 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
WO2022216915A1 (en) * | 2021-04-08 | 2022-10-13 | Sana Biotechnology, Inc. | Cd8-specific antibody constructs and compositions thereof |
-
2023
- 2023-10-04 WO PCT/EP2023/077477 patent/WO2024074571A1/en unknown
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6180370B1 (en) | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
US5693762A (en) | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5882877A (en) | 1992-12-03 | 1999-03-16 | Genzyme Corporation | Adenoviral vectors for gene therapy containing deletions in the adenoviral genome |
WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
WO1995014785A1 (en) | 1993-11-23 | 1995-06-01 | Rhone-Poulenc Rorer S.A. | Composition for the in vivo production of therapeutic products |
WO1996022378A1 (en) | 1995-01-20 | 1996-07-25 | Rhone-Poulenc Rorer S.A. | Cells for the production of recombinant adenoviruses |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO2002043478A2 (en) | 2000-11-30 | 2002-06-06 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7338660B2 (en) | 2001-11-09 | 2008-03-04 | Abgenix, Inc. | Methods of treating cancer and enhancing immune responses with antibodies that bind CD40 |
US20160031988A1 (en) | 2007-02-02 | 2016-02-04 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
WO2010009346A2 (en) | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
WO2010104749A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
WO2010104747A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted vaccines |
WO2011032161A2 (en) | 2009-09-14 | 2011-03-17 | Baylor Research Institute | Vaccines directed to langerhans cells |
US20120039916A1 (en) | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
WO2012059882A2 (en) | 2010-11-05 | 2012-05-10 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
WO2022216915A1 (en) * | 2021-04-08 | 2022-10-13 | Sana Biotechnology, Inc. | Cd8-specific antibody constructs and compositions thereof |
Non-Patent Citations (36)
Title |
---|
"GenBank", Database accession no. AY988601.1 |
"Monoclonal Antibodies For Cancer Detection And Therapy", 1985, ACADEMIC PRESS, article "Analysis, Results, and Future Prospective of the Therapeutic Use of RadiolabeledAntibody In Cancer Therapy" |
"Remington's Pharmaceutical-Sciences", 1980, MACK PUBLISHING CO. |
AMAYA MOUSHIMI ET AL: "Vaccines to Emerging Viruses: Nipah and Hendra", vol. 7, no. 1, 29 September 2020 (2020-09-29), USA, pages 447 - 473, XP093033065, ISSN: 2327-056X, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782152/pdf/nihms-1770104.pdf> DOI: 10.1146/annurev-virology-021920-113833 * |
ARNON ET AL.: "Monoclonal Antibodies And Cancer Therapy", September 1985, LISS, INC., article "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy," |
AXUP, J.Y., BAJJURI, K.M., RITLAND, M., HUTCHINS B.M., KIM, C.H., KAZANE, S.A., HALDER, R., FORSYTH, J.S., SANTIDRIAN, A.F., STAFI: "Synthesis of site-specific antibody-drug conjugates using unnatural amino acids", PROC. NATL. ACAD. SCI. USA, vol. 109, 2012, pages 16101 - 16106, XP055076259, DOI: 10.1073/pnas.1211023109 |
BABON ET AL., NAT. MED, 2016 |
BABON ET AL., NAT. MED., 2016 |
BERKERS ET AL., J. IMMUNOL., 2015 |
CHUA, K. B. ET AL.: "Nipah virus: a recently emergent deadly paramyxovirus.", SCIENCE, vol. 288, no. 5470, 2000, pages 1432 - 1435, XP002970802, DOI: 10.1126/science.288.5470.1432 |
DELONG ET AL., SCIENCE, 2016 |
DEVNATH POPY ET AL: "The pathogenesis of Nipah virus: A review", MICROBIAL PATHOGENESIS, vol. 170, 1 September 2022 (2022-09-01), US, pages 105693, XP093031611, ISSN: 0882-4010, DOI: 10.1016/j.micpath.2022.105693 * |
FOSTER STEPHANIE L. ET AL: "A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease", vol. 119, no. 12, 22 March 2022 (2022-03-22), XP093031607, ISSN: 0027-8424, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944267/pdf/pnas.202200065.pdf> DOI: 10.1073/pnas.2200065119 * |
FOSTER, STEPHANIE L. ET AL.: "A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 119, no. 12, 2022, pages e2200065119, XP093031607, DOI: 10.1073/pnas.2200065119 |
FRANCISCO J A ET AL., CANCER RES, vol. 60, 2000, pages 3225 - 31 |
GURLEY, EMILY S. ET AL.: "Person-to-person transmission of Nipah virus in a Bangladeshi community.", EMERGING INFECTIOUS DISEASES, vol. 13, no. 7, 2007, pages 1031 |
HARCOURT BH ET AL., EMERGING INFECT. DIS., 2005 |
HELLSTROM ET AL.: "Sequences of Proteins of Immunological Interest", 1987, US DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH, article "Antibodies For Drug Delivery," |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 |
JUNUTULA ET AL., NAT BIOTECHNOL., vol. 26, 2008, pages 925 - 32 |
JUNUTULA, JRFLAGELLA, K.M.GRAHAM, R.A.PARSONS, K.L.HA, E.RAAB, H.BHAKTA, SNGUYEN, T.UGGER, D.L.,LI, G. ET AL.: "Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer", CLIN. CANCER RES., vol. 16, 2010, pages 4769 - 4778, XP002727053, DOI: 10.1158/1078-0432.CCR-10-0987 |
LO, MICHAEL K., ET AL.: "Characterization of Nipah virus from outbreaks in Bangladesh, 2008 2010.", EMERGING INFECTIOUS DISEASES, vol. 18, no. 2, 2012, pages 248 |
LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859 |
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
NEEDLEMANSAUL B.WUNSCH, CHRISTIAN D.: "A general method applicable to the search for similarities in the amino acid sequence of two proteins", JOURNAL OF MOLECULAR BIOLOGY, vol. 48, no. 3, 1970, pages 443 - 53 |
PATON ET AL., LANCET., vol. 354, no. 9186, 9 October 1999 (1999-10-09), pages 1253 - 6 |
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596 |
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329 |
STEINMAN ET AL., ANN. REV. IMMUNOL., vol. 9, 1991, pages 271 |
THORPE ET AL., IMMUNOL. REV., vol. 62, 1982, pages 119 - 58 |
THORPE, ET AL.: "Monoclonal Antibodies '84: Biological And Clinical Applications", 1985, article "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review" |
VAN DOREMALEN NEELTJE ET AL: "ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys", BIORXIV, 20 July 2021 (2021-07-20), pages 1 - 22, XP093033072, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.07.20.452991v1.full.pdf> [retrieved on 20230320], DOI: 10.1101/2021.07.20.452991 * |
VIGNERON ET AL., SCIENCE, 2004 |
WARREN ET AL., SCIENCE, 2006 |
YIN WENJIE ET AL: "Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells", EBIOMEDICINE, vol. 5, 1 March 2016 (2016-03-01), pages 46 - 58, XP055799296, DOI: 10.1016/j.ebiom.2016.01.029 * |
YONEDA M ET AL: "Recombinant Measles Virus Vaccine Expressing the Nipah Virus Glycoprotein Protects against Lethal Nipah Virus Challenge", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 8, no. 3, 1 March 2013 (2013-03-01), pages e58414 - 1, XP002699590, ISSN: 1932-6203, [retrieved on 20130314], DOI: 10.1371/JOURNAL.PONE.0058414 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210032367A1 (en) | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity | |
ES2602263T3 (en) | Human monoclonal antibody for human CD134 (OX40) and procedures for preparing and using it | |
CN105669838B (en) | Neutralizing epitopes from varicella-zoster virus gE protein and antibodies thereto | |
US20230212231A1 (en) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes | |
US20240226291A9 (en) | Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus | |
EP2582389B1 (en) | High affinity human antibodies to human cytomegalovirus (cmv) gb protein | |
US20240010739A1 (en) | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes | |
US20240124532A1 (en) | Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes | |
WO2024074571A1 (en) | Dc-targeting vaccine against nipah virus infection | |
US20240131138A1 (en) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells | |
KR20240103030A (en) | Universal Sarbecovirus Vaccine | |
CN117295761A (en) | Antibodies conjugated or fused to receptor binding domains of SARS-COV-2 spike protein and their use for vaccine purposes | |
EP4282880A1 (en) | Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof | |
CN116710127A (en) | Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) polypeptides and their use for vaccine purposes | |
WO2022162012A2 (en) | Antibodies broadly targeting coronaviruses and uses thereof | |
WO2022161598A1 (en) | Antibodies broadly targeting coronaviruses and uses thereof | |
WO2023064841A1 (en) | Antibodies for use against sars-cov-2 | |
CN116606373A (en) | Novel coronavirus neutralizing antibodies and uses thereof | |
JP2022537544A (en) | Monoclonal antibody against JC virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23783875 Country of ref document: EP Kind code of ref document: A1 |